Clinical significance of FBXW7 loss of function in human cancers

Jingyi Fan1,2,3, Marcia Bellon4, Mingyi Ju2,3, Lin Zhao2,3, Minjie Wei2,3, Liwu Fu1* and Christophe Nicot4*

Abstract

FBXW7 (F-Box and WD Repeat Domain Containing 7) (also referred to as FBW7 or hCDC4) is a component of the Skp1-Cdc53 / Cullin-F-box-protein complex (SCF/β-TrCP). As a member of the F-box protein family, FBXW7 serves a role in phosphorylation-dependent ubiquitination and proteasome degradation of oncoproteins that play critical role(s) in oncogenesis. FBXW7 affects many regulatory functions involved in cell survival, cell proliferation, tumor invasion, DNA damage repair, genomic instability and telomere biology. This thorough review of current literature details how FBXW7 expression and functions are regulated through multiple mechanisms and how that ultimately drives tumorigenesis in a wide array of cell types. The clinical significance of FBXW7 is highlighted by the fact that FBXW7 is frequently inactivated in human lung, colon, and hematopoietic cancers. The loss of FBXW7 can serve as an independent prognostic marker and is significantly correlated with the resistance of tumor cells to chemotherapeutic agents and poorer disease outcomes. Recent evidence shows that genetic mutation of FBXW7 differentially affects the degradation of specific cellular targets resulting in a distinct and specific pattern of activation/inactivation of cell signaling pathways. The clinical significance of FBXW7 mutations in the context of tumor development, progression, and resistance to therapies as well as opportunities for targeted therapies is discussed.

Keywords: FBXW7, FBW7, CDC4, MYC, NOTCH, Cyclin E, MCL-1, Cancer, Tumor suppressor, Mutation, Epigenetic, Non-coding RNA, miRNA, circRNA, LncRNA, Apoptosis, DNA repair, Cell cycle, Chromosome instability, Centrosome, Aneuploidy, Immunotherapy, Drug resistance

Background

The FBXW7 gene is located at chromosome 4q31q.3 and consists of 4 untranslated introns and 13 coding exons. There are three isoforms of FBXW7, namely FBXW7-α, FBXW7-β and FBXW7-γ that are predominantly localized in the nucleus, cytoplasm, and nucleolus, respectively. Their structural divergence is manifested by differences in the first exon, while the role of these isoforms has been previously reviewed [1]. The alpha form is the most abundant isoform and accounts for the most substrate turnover. Structurally FBXW7 is composed of seven WD40 domains involved in substrate binding, and a dimerization domain and F-box domain involved in the recruitment of SCF components for E3 ligase activity. FBXW7 interacts with substrates through a conserved sequence known as the CDC4 phosphodegron (CPD) motif. Glycogen synthase kinase 3 beta (GSK3β)-mediated phosphorylation of cellular targets is a required step for the recruitment of FBXW7, ubiquitination, and proteasome degradation of substrates [2]. FBXW7 can function as monomer or as a dimer and some studies have suggested that this may affect target selection and binding strength. In addition, dimerization of FBXW7 may play important roles in cancer cells...
whereby one copy is mutated. In fact, several studies have shown dominant negative functions for mutated FBXW7 alleles. FBXW7 is frequently inactivated in human cancers through genetic and epigenetic mechanisms, along with post transcriptional modifications. Subsequently, inactivation of FBXW7 is a major cause of carcinogenesis and the development of human cancers. Numerous studies have demonstrated that loss of FBXW7 is strongly associated with carcinogenesis, tumor metastasis, poorer outcomes in cancer patients, and resistance to chemotherapies. Therefore, FBXW7 expression is an independent prognostic biomarker of poorer outcomes in some cancers.

This review will focus on current and past literature. The regulation of FBXW7 through transcriptional and post-transcriptional means will be highlighted first, to get a better appreciation of the complex regulatory role of FBXW7. Known FBXW7 target proteins will then be discussed, highlighting their correlation with known oncogenic pathways involved in carcinogenesis. Finally, a detailed analysis of the current understanding of FBXW7 in individual cancers, including current therapies used to target FBXW7 will be deliberated.

The regulation of FBXW7 expression in normal and cancer cells

Transcriptional regulation of FBXW7

Studies have shown that multiple transcription factors can regulate the expression of FBXW7 isoforms [3–9]. There is a diverse array of FBXW7 transcriptional regulators that include known transcriptional activators (TP53 and C/EBPδ), transcriptional repressors (PHF1 and Hes5), ligands (TGFβ) and ATPase super family (TRIP13) proteins. Most of these factors negatively regulate FBXW7 expression. TRIP13 (Thyroid Hormone Receptor Interacting Protein 13) belongs to a protein superfamily that is overexpressed in many human cancers and is associated with poor prognosis in cancer patients [10]. Among the many roles of TRIP13, are involvement in the DNA damage response and the spindle assembly checkpoint (SAC) [11]. TRIP13 can also bind directly to the FBXW7 promoter and can mediate transcriptional repression of the FBXW7 promoter (Fig. 1) [10, 12]. An additional factor that directly interacts with the FBXW7 promoter region is PHF1 (PHD finger protein 1) (Fig. 1). PHF1 is a reader for histone arginine methylation, which targets PHF1 to the chromatin. PHF1 binds to the promoter region of FBXW7 and represses transcription via a complex that consists of PHF1, a methyltransferase (PRMT5; protein arginine methyltransferase 5), and ubiquitin ligase (Cullin 4B) complex [13]. Like PHF1, Hes5 (hes family bHLH transcription factor 5) is also a known transcriptional repressor. Hes5 acts downstream of NOTCH signaling and suppresses FBXW7 expression resulting in a negative regulatory loop [14]. In addition, Hes5-mediated suppression of FBXW7 has also been linked to TGIF1 (Transforming Growth Factor-Beta-Induced Factor) degradation and inactivation of the TGF-β signaling pathway [15].

Several known transcriptional activators also play roles in FBXW7 transcriptional regulation. Though C/EBPδ (CCAAT/enhancer-binding protein-δ) usually activates transcription, a reverse role has been shown for FBXW7 transcription. C/EBPδ directly inhibits the FBXW7 promoter and enhances the mTOR/AKT/S6K1 signaling pathway. This leads to augmented translation and activity of HIF-1α (hypoxia-inducible factor-1α), with a resulting increase in cell migration and metastasis [3]. In contrast to C/EBPδ, C/EBPa and C/EBPβ appear to have no effect on FBXW7 promoter expression. Several studies have also reported a regulatory loop between the tumor suppressor p53 (TP53) and FBXW7 [16, 17]. The first exon of FBXW7 contains a p53-binding site which acts as a positive regulator of transcription [7]. However, in response to DNA damage induced activation of ATM (ATM Serine/Threonine Kinase), p53 is phosphorylated. This action generates a signal for FBXW7 interaction and degradation thereby creating a negative feedback regulatory loop [17]. Under normal physiological conditions p53-mediated activation of FBXW7 plays essential roles in the control of cell cycle and DNA strand break repair.

Epigenetic regulation of FBXW7

Epigenetic inactivation of tumor suppressor genes by promoter hypermethylation is a frequent event during tumorigenesis [18]. The Human Disease Methylation Database demonstrates an inferred or potential disease association between FBXW7 methylation and several diseases (Fig. 2). This is especially true for malignant pluripotent embryonal carcinoma. Among the three isoforms of FBXW7, epigenetic regulation of FBXW7-β through methylation is the most common. This is likely due to the differential expression of FBXW7-β in tissues and cells. The promoter of FBXW7-β has been reported to be epigenetically regulated by DNA and histone modifications and is methylated in a variety of cancers, particularly in primary breast cancer cells [19]. Further studies demonstrate a role for FBXW7 methylation in thymic tumors. Methylation levels of FBXW7-β differ among progressive tumor samples; and methylation of FBXW7-β is positively correlated with tumor malignancy. This suggests that methylation inhibition of FBXW7-β is a potential cause of thymic tumor progression [20–22].

As discussed above, PRMT5 is a methyltransferase involved in PHF1 regulation of FBXW7 transcriptional levels. PRMT5 symmetrically links two methyl
groups onto arginine residues on histones H3 and H4. These marks are generally associated with transcriptional repression [23]. Studies have shown that PRMT5 increases the occupancy of heterochromatin markers H4R3me2 and H3K9me3 and decreases the occupancy of the euchromatin marker H3K9ac onto the FBXW7 promoter. This results in epigenetic silencing of FBXW7 mRNA expression [24]. In fact, PRMT5 expression is inversely correlated with FBXW7 and closely associated with aberrant MYC function in human cancers [25]. This suggests that PRMT5, or related epigenetic factors, may represent potential therapeutic targets in a subset of tumors bearing silenced wild type FBXW7 gene.

**FBXW7 regulation at the mRNA level**

RNA stability, mRNA degradation, and translation can be regulated by the m^6^A methyltransferase complex. N6-methyladenosine (m^6^A) is a reversible, ubiquitous mRNA methylation modification. This m^6^A methyltransferase complex contains several enzymes that are known as “writers”, adding m^6^A onto mRNA [26]. One of these enzymes, METTL3 (Methyltransferase-Like Protein 3), can stimulates m^6^A methylation in the mRNA coding sequence of FBXW7 [27]. This leads to increased translational efficiency of FBXW7 mRNA, allowing METTL3 to act as a positive regulator of FBXW7.

Piwi is a subfamily of Argonaute proteins with important roles in stem cells, differentiation, and epigenetic regulation. Piwi proteins can bind small RNAs. Among the Piwi family, PiwiL1 (Piwi Like RNA-Mediated Gene Silencing 1), is overexpressed in glioma stem-like cells (GSCs). In GSCs, PiwiL1 was found to negatively regulate the mRNA stability of FBXW7 [28] (Fig. 1). Unlike its role with other mRNAs, PiwiL1 did not bind to FBXW7 mRNA directly, and was likely inhibiting FBXW7 indirectly through another mRNA.
Non-coding RNA Regulation of FBXW7

Multiple non-coding RNAs (ncRNAs) also regulate the expression of FBXW7 [29]. While some ncRNAs are essential for standard protein translation, including transfer RNAs (tRNAs) and ribosomal RNAs (rRNA), other ncRNAs have gene regulatory roles, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). In general, ncRNAs are not translated into protein; however, some circRNAs have been shown to encode smaller forms of the parent protein. MicroRNAs play an important regulatory role in tumorigenesis and development [30–32]. By interacting with the 3’UTR of target mRNAs, miRNAs achieve post-transcriptional repression of mRNA translation, thereby regulating many biological processes including proliferation, apoptosis, invasion/metastasis, and angiogenesis [30]. miRNAs act mostly as negative regulators of FBXW7 expression and generally display a pro-oncogenic role. Numerous miRNAs have been shown to target FBXW7 in various cells, tissues, and cancers. Among these are miR-25-3p, miR-32, miR-92b, miR-96, miR-155-3p, miR-182, miR-223, and miR-367. An expanded list of miRNAs targeting FBXW7 is included in Table 1. It is likely this list will grow as the study of FBXW7-miRNA interaction(s) expands. While each of these FBXW7-targeting miRNAs were discovered in individual cancers, it is still unknown whether they possess broad regulatory roles for FBXW7 expression in all cancers. Several studies have demonstrated a roll for miR-223 in regulating FBXW7 expression, suggesting miR-223 has a broad capacity to target FBXW7 across various tissues and disease. TAL1 (T-Cell Acute Lymphocytic Leukemia Protein 1), one of the most frequently dysregulated oncogenes in T-ALL (T-cell acute lymhoblastic leukemia), has been shown to induce expression of miR-223 and repress expression of FBXW7 [33]. In addition, miRNA-223-induced inhibition of the FBXW7 has been shown in solid tumors as well. miR-223 affects the proliferation and apoptosis of colorectal cancer cells via activation of the NOTCH and AKT/mTOR pathways [33–36]; and inhibits FBXW7 in oesophageal squamous cell carcinoma [37]. MYC-regulated miRNA-92b and miR-92a have also been shown to inhibit FBXW7 expression in colorectal cancer cells [38, 39]. The same is true for miR-92a regulation of
| RNA type | ncRNA    | Research subject                      | FBXW7 expression | Results or effects of the research                                                                 | References |
|----------|----------|----------------------------------------|------------------|---------------------------------------------------------------------------------------------------|------------|
| miRNAs  | miR-18b-3p | Hepatic fibrosis                        | down-regulated   | Promote liver fibrosis, promote tumor proliferation, and promote inflammation                    | [41]       |
|         | miR-23a   | Colorectal cancer                       | down-regulated   | Promote malignant transformation of colorectal cancer                                             | [42]       |
|         | miR-25    | Hepatocellular Carcinoma                | down-regulated   | Invasion and migration                                                                             | [43]       |
|         | miR-25    | Prostatic Small Cell Neuroendocrine Carcinoma | down-regulated   | Upregulate AURKA, promote tumor proliferation                                                     | [44]       |
|         | miR-27a   | Bronchial epithelial cell carcinoma     | down-regulated   | Malignant transformation induced by the viral oncoprotein ST                                         | [45]       |
|         | miR-27b-3p | Multiple myeloma                        | down-regulated   | Mcl-1 is upregulated and produces apoptosis resistance                                              | [46]       |
|         | miR-32    | Breast cancer                           | down-regulated   | Inhibits apoptosis and promotes proliferation and migration of breast cancer cells.                | [47]       |
|         | miR-92a   | Cervical Cancer                         | down-regulated   | Promote proliferation of cervical cancer cells                                                    | [48]       |
|         | miR-92a-3p | Colorectal cancer                       | down-regulated   | Activation of Wnt/β-catenin pathway promotes cell stemness, EMT, metastasis and S-FL/L-OHP resistance in CRC | [39]       |
|         | miR-92a-3p | Gastric cancer                          | down-regulated   | Promote invasive migration of gastric cancer                                                      | [49]       |
|         | miR-92a-3p | Hepatocellular carcinoma                | down-regulated   | Promotes proliferation and cell cycle transition from G1 to S phase, and inhibits apoptosis in HCC cells | [40]       |
|         | miR-101   | Bone marrow mesenchymal stem cell       | down-regulated   | Upregulate HIF1α                                                                                  | [50]       |
|         | miR-144   | Nasopharyngeal carcinoma                | down-regulated   | Upregulate HIF1α                                                                                  | [51]       |
|         | miR-155   | Glioma                                 | down-regulated   | Enhance the tumor cell viability                                                                  | [52]       |
|         | miR-155-3p | Hepatocellular carcinoma               | down-regulated   | Promote HCC cell proliferation                                                                   | [53]       |
|         | miR-182   | Breast cancer                           | down-regulated   | Upregulate the HIF-1α-VEGF-A axis and promotes tumor invasion and migration                         | [54]       |
|         | miR-182   | Colon adenoma                          | down-regulated   | Induced transformation of adenoma to adenocarcinoma                                              | [55]       |
|         | miR-197-3p | Gastric cancer                          | down-regulated   | Up-regulate cyclinD1, EMT, YAP1, down-regulate CCDC6                                             | [56]       |
|         | miR-223   | Gastric cancer                          | down-regulated   | Promote the cisplatin resistance; reduces trastuzumab sensitivity                                 | [36, 57]  |
|         | miR-223   | Oesophageal squamous cell carcinoma     | down-regulated   | Intervention of poor patient prognosis                                                            | [37]       |
|         | miR-223   | Colorectal cancer                       | down-regulated   | Increases endogenous cell cycle protein E protein and activity                                    | [58]       |
|         | miR-367   | Lung cancer                             | down-regulated   | Promotes tumor cell invasion and migration and is associated with poor prognosis                 | [59]       |
|         | miR-367   | Hepatocellular carcinoma                | down-regulated   | Promote EMT                                                                                      | [60]       |
|         | miR-500a-3p | Gastric cancer                          | down-regulated   | Increase cisplatin resistance                                                                    | [61]       |
|         | miR-503   | Colon adenoma                          | down-regulated   | Induced transformation of adenoma to adenocarcinoma                                              | [55]       |
|         | miR-586   | Lung cancer                             | down-regulated   | Promote tumorigenesis                                                                              | [62]       |
|         | miR-5000-3p | Laryngocarcinoma                       | down-regulated   | Promote the invasion and migration of laryngeal cancer cells                                      | [63]       |
FBXW7 in hepatocellular carcinoma (HCC); where over-expression of miR-25-3p and miR155-3p have also been shown to suppress FBXW7 mRNA expression, promoting the migration and invasion of tumor cells [40].

SREBP2 is a member of the Sterol Regulatory Element-Binding Protein (SREBP) family, which regulates cell survival and lipid synthesis. SREBP2 induces miR-96 and miR-182 that directly suppress its negative regulator FBXW7, which results in a positive feed forward loop [67]. miR-182 has also been associated with the progression of glioma and breast cancers by directly targeting FBXW7 [68, 69]; again highlighting the broad role individual miRNAs play in regulating FBXW7 across various cancers. High levels of miR-32 expression downregulate FBXW7, promote cell proliferation, migration and suppress apoptosis in breast cancer [47]. Finally, miR-367, an indicator of a poorer prognosis in NSCLC patients, stimulates tumor growth through direct inhibition of FBXW7 [59]. miR-367 also inhibits FBXW7 in HCC.

Long non-coding RNAs work intimately with miRNAs in regulating protein expression. IncRNAs can regulate the function of miRNAs by acting as a competing endogenous RNA (ceRNA) [70]. Consequently, any IncRNA that regulates the aforementioned miRNAs would be expected to act as positive regulators of FBXW7 expression and reduce the expression of FBXW7 targets. ceRNA activity can be affected by tissue expression restrictions, IncRNA abundance, subcellular localization of ceRNA components, the binding affinity of miRNAs to their targets, and through RNA modifications [71].

Table 1 (continued)

| RNA type | ncRNA       | Research subject                        | FBXW7 expression | Results or effects of the research                                                                 | References |
|----------|-------------|-----------------------------------------|------------------|---------------------------------------------------------------------------------------------------|------------|
| IncRNAs  | IncRNA-CASC2| Hepatocellular carcinoma                | up-regulated     | Inhibit EMT                                                                                       | [60]       |
| IncRNA   | MALAT1      | Glioma                                  | up-regulated     | Suppresse tumor cell viability                                                                   | [52]       |
| IncRNA   | MIF         | Lung cancer                             | up-regulated     | Inhibit cMyc, inhibits aerobic glycolysis and tumorigenesis                                       | [62]       |
| IncRNA   | MIR22HG     | Laryngocarcinoma                        | up-regulated     | Inhibit the invasion and migration of laryngeal cancer cells                                     | [63]       |
| IncRNA   | MT1JP       | Gastric cancer                          | up-regulated     | Inhibit invasive migration of gastric cancer                                                     | [49]       |
| IncRNA   | FRE1L4      | Gastric cancer                          | up-regulated     | Inhibit prostate cancer progression                                                              | [49]       |
| IncRNA   | TTN-AS1     | Esophageal Squamous Cell Carcinoma      | up-regulated     | Competitive binding of miR-133b promotes the expression of transcription factor Snail1, leading to an EMT cascade response | [64]       |
| circRNAs | hsa_circ_001988 | Gastric cancer                        | up-regulated     | Up-regulate cyclinD1, EMT, YAP1, down-regulate CCDC6                                              | [56]       |
| circFBXW4| Hepatic fibrosis               | up-regulated     | Inhibit liver fibrosis, inhibit tumor proliferation, anti-inflammatory                          | [41]       |
| FBXW7-185aa | Glioma                  | -                                       | Reduce the expression of c-Myc expression, associated with good patient survival                | [65]       |
| circ-FBXW7 | Colon adenoma | -                                       | Decrease the expression of NEK2, mTOR and PTEN to induce tumor suppression                      | [66]       |

The table describes all currently known regulatory roles of non-coding RNA (ncRNA), including miRNAs, Inc-RNAs and circ-RNAs, affecting FBXW7 expression which can be up-regulated or down-regulated. The cancer type and published biological consequences of FBXW7 alterations is indicated in the second and fourth columns. References for which the ncRNA was described is listed on the right end-side of the table. aFor cirRNAs, circ-FBXW7 goes by several names, including has_circ_001988 and circ_022705.
miR-92a-3p by IncRNA FER1L4 and IncRNA MT1JP has also been shown to increase expression levels of FBXW7 [49, 74]. The FER1L4/miR-92a-3p/FBXW7 axis controls apoptosis signaling in prostate cancer [74]. Although expression of miR-92a-3p is elevated in gastric cancers, the ceRNA activity of IncRNA MT1JP can efficiently prevent miR-92a-3p repression of FBXW7 mRNA expression and induce apoptosis of gastric cancer cells [75]. MT1JP is down-regulated in gastric cancer tissues and may serve as a disease progression biomarker and a potential therapeutic strategy [49].

Circular RNAs are single stranded RNAs, and unlike other IncRNAs, form a stable, covalently closed circle [76]. circRNAs have multiple functions that include protein coding and gene regulation. One of the better studied circRNAs that regulates FBXW7 is circ-FBXW7 (also known as has_circ_001988 and has_circ_022705). Circ-FBXW7 is down-regulated in primary patient cells from glioblastoma, colorectal, and gastric cancer samples, and in triple-negative breast cancer cells [56, 65, 66, 77]. A similar IncRNA, circFBXW4, also targets FBXW7 and is down-regulated in hepatic fibrosis [41]. One of the main actions of circRNAs is to sponge away miRNAs. Circ-FBXW7 works by sponging miR-18b-5p and miR-197-3p; and circFBXW4 sponges miR-18b-3p in various cancers and disease processes [41, 56, 77, 78]. All these regulatory actions lead to down-regulation of FBXW7. Among the down-stream effects of increased circ-FBXW7 are decreased proliferation and increased apoptosis and chemoresistance [78]. Interestingly, circ-FBXW7 also encodes a novel protein, FBXW7-185 aa [65]. This 22kDa protein was positively associated with glioblastoma patient overall survival and inhibited proliferation with cell cycle arrest in glioma cells [65].

**Genetic alterations of FBXW7**

Inactivation of FBXW7 by genetic mutation, genomic deletion, or promoter hypermethylation is a major cause of carcinogenesis and development of human cancers. FBXW7 demonstrates a high mutation rate in many cancers [1]. Among all family members containing F-box and WD repetitive structural domains, FBXW7 exhibits the highest mutational frequency. Meta-analysis of the COSMIC database shows that the overall mutational rate of FBXW7 in all human tumors is 7.79% (number of mutated samples n=3844 / total number of samples n=49348). Among all mutation cases in malignant tumors, 72.70% of FBXW7 mutations are missense substitutions, 13.82% are nonsense substitutions, and 7.89% are insertion/deletion mutations [79]. Figure 3 represents the percentage of occurrence of different FBXW7 alterations in various human cancer types. Almost 50% of missense and nonsense mutations are observed in hematopoietic and large intestine related cancers (Fig. 3). Although the reported numbers are relatively small, it is intriguing that the distribution of mutations in large intestinal cancer is similar between frameshift insertions and frameshift deletions while hematopoietic cancers display a 10-fold higher frequency in frameshift insertions versus frameshift deletions (Fig. 3). The FBXW7 mutations mentioned above most often occur in the FBXW7 WD40 domain [80]. Three hotspot, pathogenic, mutations have been identified in residues Arg 465, Arg 479, and Arg 505 (also known as FBXW7AGE mutations). These conserved arginine residues are present in the WD40 structural domain and may be important for proper folding of the substrate binding pocket. However, while these mutants were initially thought to be “dead” mutants, unable to interact with any targets, recent studies demonstrate that these mutants have distinct phenotypes. Among them, R465C is the most frequently detected FBXW7 mutation in human primary tumors [81].

To better demonstrate the disease distribution and probability of occurrence of FBXW7 mutations, we performed statistical analysis using the cBioportal database [82, 83] (Table 2). Even though the rate of some FBXW7 mutations is relatively low in some cancer types, the fact that identical mutations are found across multiple cancer types suggests that these are relevant and warrant additional studies. For instance, L443H was found in hematopoietic and cervical cancers [84], while H460R was detected in both hematopoietic and gastric cancers [85]. According to our analyses from the COSMIC database data, the distribution of the most frequently found FBXW7 mutations in cancers is intriguingly different in different tissues (Fig. 4). The significance and role of each of these mutations in human cancer has not been investigated in depth and warrants future studies. While hot spot mutations, R465C, R465H, R505C, and R479Q, share similar distribution patterns, it is noticeable that R505G has a significantly different distribution. R505G is mostly detected in upper aerodigestive tract cancers (30.22%), urinary tract cancers (23.02%) and lung cancers (18.7%). Aerodigestive tract cancers were 10 times less frequent for R505C mutation (3.11%). Lung cancer and urinary tract cancers rarely had the FBXW7 mutation, R505C, with less than 1% of all cancers having this mutation. The fact that R505C and R505G have different representation among human cancers is likely a reflection of the differences in the ability of these mutants to bind and stimulate target degradation. Although the numbers are small, it is intriguing that some mutations appear to be more frequent in specific cancers. For example, cervical cancers were associated with R505G or R658*, breast cancer with S582L, oesophageal cancers with R278*,...
pancreatic cancer with R367*, and glioblastoma with R658* mutations. Additional studies that include larger cohorts are needed to validate these observations. In contrast, large intestinal cancers are equally distributed across FBXW7 mutations, except for R505G.

Current studies demonstrate that some mutations in FBXW7 do not exhibit a complete loss of function and demonstrate specific selectivity for ubiquitinated substrates. Among them, the S462P, H468R, R465C and R479Q mutations of FBXW7 show similar effects and fail to induce degradation of any known target. In contrast, R505C retains the ability to bind to and degrade BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), but not NOTCH1, c-MYC, cyclin E, or MCL1. The W425R and L443F FBXW7 mutants can specifically induce the degradation of MCL1, but not other targets [86]. These observations suggest that mutations in FBXW7 may introduce a selective degradation pattern of target proteins, which is associated with the genetic background present in each tumor cell(s). This further suggests that certain FBXW7 targeted oncogenes, may be more necessary in individual cancers, than others. This would then suggest why certain cancers have a propensity for a particular FBXW7 mutation, in which certain pro-survival functions are required. Finally, recent studies have reported gain of function mutations for FBXW7. The FBXW7 mutants D510E and D527G were found to only degrade NOTCH1 [87]. Surprisingly, these mutants were associated with an oncogenic phenotype and cooperated with viral and/or cellular oncogenes in colony formation assays and in vivo tumor growth [87]. This functional difference between FBXW7 mutants implies that future research on FBXW7 mutations should be directed towards a more in-depth and refined course. It may be necessary to differentiate mutation types and functions of different mutants to clearly distinguish between fully inactivating mutations and those with partially inactivating mutations. These studies will have important implications for cancer treatment by targeting appropriate signaling pathways activated in tumor cells.

Fig. 3 FBXW7 Genetic Mutations in Various Cancer Types. The FBXW7 gene occurs in a variety of mutation patterns including nonsense mutations, deletion mutations, and mixed mutation patterns that show different frequencies in different tumor types. Here is the distribution of different mutation patterns of FBXW7 in tissues.
### Table 2: Most frequent FBXW7 mutations in human tumors

| Protein Change | Cancer Type | Mutation Type | Mutation Frequency | Sample Size |
|----------------|-------------|---------------|--------------------|-------------|
| R14Q           | Colon Adenocarcinoma | Missense | 0.34 | 5120 |
| X195_splice    | Uterine Endometrioid Carcinoma | Splice | 0.42 | 1078 |
|                | Stomach Adenocarcinoma | Splice | 0.31 | 1351 |
| R224Q          | Uterine Endometrioid Carcinoma | Missense | 0.3 | 8236 |
| G423V          | Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma | Missense | 0.3 | 185 |
| R441Q          | Uterine Endometrioid Carcinoma | Missense | 0.3 | 13882 |
| R465C          | Rectal Adenocarcinoma | Missense | 0.43 | 1081 |
|                | Uterine Endometrioid Carcinoma | Missense | 0.42 | 7291 |
|                | Stomach Adenocarcinoma | Missense | 0.33 | 638 |
| R46SH          | Colon Adenocarcinoma | Missense | 0.31 | 1119 |
|                | Mucinous Adenocarcinoma of the Colon and Rectum | Missense | 0.61 | 1622 |
|                | Uterine Endometrioid Carcinoma | Missense | 0.44 | 1558 |
|                | Stomach Adenocarcinoma | Missense | 0.43 | 2689 |
|                | Serous Ovarian Cancer | Missense | 0.41 | 799 |
|                | Rectal Adenocarcinoma | Missense | 0.39 | 9464 |
|                | Colon Adenocarcinoma | Missense | 0.37 | 1208 |
| R479G          | Cervical Squamous Cell Carcinoma | Missense | 0.6 | 167 |
|                | Bladder Urothelial Carcinoma | Missense | 0.41 | 165 |
| R479L          | Head and Neck Squamous Cell Carcinoma | Missense | 0.62 | 257 |
| R479P          | Cervical Squamous Cell Carcinoma | Missense | 0.33 | 162 |
| R479Q          | Uterine Endometrioid Carcinoma | Missense | 0.6 | 1322 |
|                | Uterine Mixed Endometrial Carcinoma | Missense | 0.45 | 816 |
| R505C          | Cervical Squamous Cell Carcinoma | Missense | 0.53 | 296 |
|                | Uterine Endometrioid Carcinoma | Missense | 0.48 | 4835 |
|                | Stomach Adenocarcinoma | Missense | 0.43 | 1705 |
|                | Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma | Missense | 0.38 | 1512 |
|                | Esophageal Adenocarcinoma | Missense | 0.38 | 1709 |
| R505G          | Endocervical Adenocarcinoma | Missense | 0.75 | 1112 |
|                | Bladder Urothelial Carcinoma | Missense | 0.61 | 416 |
|                | Colon Adenocarcinoma | Missense | 0.5 | 117 |
|                | Lung Squamous Cell Carcinoma | Missense | 0.33 | 335 |
|                | Cervical Squamous Cell Carcinoma | Missense | 0.33 | 672 |
| R505H          | Uterine Endometrioid Carcinoma | Missense | 0.54 | 450 |
|                | Colon Adenocarcinoma | Missense | 0.34 | 108 |
| R505L          | Head and Neck Squamous Cell Carcinoma | Missense | 0.56 | 345 |
| D520E          | Uterine Endometrioid Carcinoma | Missense | 0.41 | 7858 |
| D520N          | Bladder Urothelial Carcinoma | Missense | 0.38 | 530 |
| D520Y          | Colon Adenocarcinoma | Missense | 0.27 | 5120 |
| Y545C          | Breast Invasive Ductal Carcinoma | Missense | 0.72 | 171 |
|                | Head and Neck Squamous Cell Carcinoma | Missense | 0.43 | 79 |
|                | Uterine Endometrioid Carcinoma | Missense | 0.4 | 63 |
|                | Uterine Endometrioid Carcinoma | Missense | 0.36 | 498 |
| S546L          | Bladder Urothelial Carcinoma | Missense | 0.76 | 1294 |
| S582L          | Rectal Adenocarcinoma | Missense | 0.7 | 138 |
| R658*          | Uterine Endometrioid Carcinoma | Nonsense | 0.7 | 712 |
| R658*          | Colon Adenocarcinoma | Nonsense | 0.4 | 169 |
| R658*          | Rectal Adenocarcinoma | Nonsense | 0.41 | 11437 |
| R658*          | Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor | Nonsense | 0.37 | 6856 |
| R658*          | Uterine Endometrioid Carcinoma | Nonsense | 0.21 | 10826 |
FBXW7 shows distinct mutational probabilities in different cancers. According to the clinical information related to FBXW7 in the cBioportal database, of the TCGA Pan Cancer dataset, FBXW7 has mutations in a wide variety of cancers (Fig. 5A). Mutations within FBXW7 can mediate the poor prognosis of tumor therapy through multiple pathways. In colorectal cancer, mutations of FBXW7 can lead to immune escape from lytic T-cell immunosurveillance. This results in poor survival in colorectal cancer patients [88]. Similar observations have been made in studies related to mesothelioma [89]. In lung squamous cell carcinoma, mutations in the FBXW7 gene have been observed to affect survival in experimental animal models [90]. Lung squamous cell
datasets show that mutations in FBXW7 significantly affect patient survival (Fig. 5B). This correlation between FBXW7 mutations and disease prognosis is even more explicit for ovarian serous carcinoma; whereby FBXW7 can be used as an independent prognostic indicator [91]. This association was further validated by the cBioportal for the TCGA ovarian serous cystadenocarcinoma data set (TCGA, Nature 2011), and the results showed that FBXW7 mutations may be an important factor affecting ovarian serous carcinoma (Fig. 5C). Next generation sequencing also identified FBXW7 as a potential therapeutic target for bladder cancer [92], which was validated in bladder uroepithelial carcinoma datasets (cBioportal, TCGA, Firehose Legacy) (Fig. 5D). In a comprehensive analysis of multiple data sets on colorectal cancer, it was also verified that mutations in FBXW7 mediated poor prognosis in colorectal cancer (Fig. 5E), which is consistent with the close association of FBXW7 mutations with colorectal cancer mentioned previously. Besides solid tumors, FBXW7 mutations also have an adverse effect on survival in adult T-cell leukemia (ATL) cells [86]. In addition, several T-cell leukemia (T-ALL)-related studies have indicated that mutations in FBXW7 are associated with poor prognosis in T-ALL [93–96].

**Clinical significance of FBXW7 mutations**

There is a strong association between inactivation of FBXW7 and the development of drug resistance in the treatment of tumors [90, 97]. However, there are differences in the extent to which FBXW7 mutations affect the drug resistance of different therapeutic agents. The Genomics of Drug Sensitivity in Cancer (GDSC) database can expose the association between FBXW7 mutations and drug sensitivity through ANOVA analysis. In fact, such analysis of the GDSC data shows that FBXW7 mutations have a particularly significant effect on the sensitivity of therapeutic drugs (Table 3). Although loss of FBXW7 is relevant to most human cancers, this section will focus on those most frequently associated cancers with FBXW7 mutations.
Colorectal carcinoma (CRC) progression demonstrates a strong negative correlation with FBXW7 expression [98]. Recent genome sequencing studies suggest that as much as 16% of CRC patients demonstrate mutation(s) in FBXW7 [99]. In metastatic CRC patients the loss of FBXW7 is associated with shorter overall survival (OS) and drug resistance [100]. In a retrospective CRC study, comparing cancer tissues and their paired adjacent non-cancerous tissues, FBXW7 expression was negatively associated with lymph node metastasis and TNM stages [101]. A meta-analysis involving 4199 patients predicted poor OS but no significant change in disease-free survival (DFS) in CRC patient with loss of FBXW7 [102]. Furthermore, multivariate Cox regression analyses from several studies suggests that FBXW7 expression is an independent prognostic biomarker of poorer outcome for CRC patients [103, 104]. These observations are corroborated by preclinical and in vitro studies. Numerous in vitro studies from multiple laboratories have demonstrated that loss of FBXW7 in colon cancer cells is significantly associated with resistance to drug therapies. These treatments included, PD-1 antibody, Taxol, Oxaliplatin, RAS/RAF/MEK/ERK signaling multi-kinase inhibitors, and irinotecan (CPT-11) [105–109]. These results demonstrate significant clinical challenges posed by the loss of FBXW7 expression in tumor cells.

Endometrial cancers (ECs) are aggressive tumors that frequently harbor somatic missense mutations in FBXW7 [110]. FBXW7 mutations are found in up to 30% of serous ECs, 28% of uterine carcinosarcomas, 25% of clear cell ECs, and 10% of endometrioid ECs. Studies have demonstrated that loss of the phosphatase, PP2A (Protein Phosphatase 2 Phosphatase Activator) or FBXW7 constitute drivers in EC progression [111, 112]. Furthermore, FBXW7 mutations were strongly associated with late-stage, vascular invasion, and lymph node metastasis [113]. These findings and related studies suggest that FBXW7 deficiency mediates poor progression of EC; and is associated with resistance problems related to therapies including PD-1 inhibitors [105].

The expression of FBXW7 shows a significant correlation with the treatment outcome of non-small cell lung cancer (NSCLC) [114–116]. Whole-exome sequencing and comprehensive immunoassays of early-stage lung squamous carcinoma reveals a significant decrease in FBXW7 expression levels, suggesting that FBXW7 may be one of the key factors influencing the progression of lung squamous carcinoma [115]. Cancer Genome Atlas data suggests that deletion of FBXW7 occurs in 31% of lung adenocarcinomas (LADC) and 63% of lung squamous cell carcinomas (LSCC). Loss of FBXW7 promotes the development and progression of LSCC and LADC through activation of KRAS and contributes to hyperactivation of NF-κB, which increase resistance to cisplatin treatment [90] as well as anti-EGFR therapies such as Gefitinib, Cetuximab, or Panitumumab. Finally, additional studies show that hyperactivation of ERK1/2 signaling decreases FBXW7 protein stability and prevents

### Table 3

| Drug         | Drug Target                  | IC50 mut-FBXW7 | IC50 wt-FBXW7 | P-value |
|--------------|------------------------------|----------------|---------------|---------|
| UNC0638      | G9a and GLP methyltransferases| 24.909         | 19.849        | 0.000999|
| KIN001-266   | MAP3K8                       | 32.119         | 20.622        | 0.0265  |
| Temsirolimus | MTOR                         | 0.3013         | 0.13204       | 0.0244  |
| BIX02189     | MEK5, ERK5                   | 97.184         | 79.736        | 0.0232  |
| Tubastatin A | HDAC1, HDAC6, HDAC8          | 149.28         | 108.77        | 0.0254  |
| Shikonin     | not defined                  | 1.4784         | 0.94584       | 0.0109  |
| KIN001-042   | GSK3B                        | 114.01         | 89.295        | 0.0477  |
| THZ-2-49     | CDK9                         | 36.568         | 11.993        | 0.0246  |
| KIN001-042   | GSK3B                        | 114.01         | 89.295        | 0.0289  |
| JAK1_3715    | JAK1                         | 109.83         | 79.93         | 0.0394  |
| Tanespimycin | HSP90                        | 0.93356        | 0.45133       | 0.0261  |
| OSI-930      | KIT                          | 77.599         | 60.839        | 0.0325  |
| AICA         | AMPK agonist                 | 3268.4         | 2217.1        | 0.0349  |
| Ribonucleotide| not defined                  | 3268.4         | 2217.1        | 0.0349  |
| Venetoclax   | BCL2                         | 9.8217         | 9.1615        | 0.0209  |
| WEHI-539     | BCL-XL                       | 35.43          | 34.404        | 0.0263  |

This table list drugs with resistance caused by FBXW7 mutations adapted from the GDSC database (https://www.cancerrxgene.org/). The name of the drug is listed along with the pathway targeted. Only data with P values of less than 0.05 were considered.
degradation of phosphorylated HSF1 (Heat Shock Transcription Factor 1). This in turn, stimulates transcription of multi-drug resistance receptor (MDR1) gene and drug resistance, which affects the treatment of NSCLC. A high mutation rate of FBXW7 has been reported in hematopoietic cancers, with 20% of T-cell non-Hodgkin lymphoma (T-NHL), 14% of T-cell acute lymphoblastic leukemia (T-ALL) and 10% of HTLV-I-associated acute T-cell leukemia (ATL) patient's cells harboring FBXW7 mutations. In a preclinical study, FBXW7 mutations R505C, R465H, R465C, or R479Q conferred resistance to gamma secretase inhibitor (GSI), MRK-300, in T-ALL. The underlying resistance mechanism was found to be related to the inability of mutated FBXW7 to target NOTCH and c-MYC for proteasome degradation [117]. In a preclinical study, adult T cell leukemia cells expressing FBXW7 mutants W425R, S462P, and H468R demonstrated resistance to BET inhibitors JQ1 and Birabresib (OTX015). This was associated with increased phosphorylation of BRAF, MEK, and ERK, and increased expression of Stat3 and MYC.

FBXW7 mutations have also been detected with a rate of 8% in melanoma patients [118]. Like CRC cells, in a preclinical study, loss of FBXW7 was associated with resistance to immunotherapy treatment with PD-1 antibody [119]. In an additional clinical case study, a melanoma patient treated with Keytruda (Pembrolizumab) demonstrated a response in all skin lesions but one [105]. Genome sequencing revealed that the lesion resistant to Keytruda was mutated for FBXW7 at R505C.

**Post-transcriptional regulation of FBXW7**

FBXW7 expression is also regulated post-transcriptionally at the protein level. FBXW7 can be phosphorylated by several proteins, leading to loss of dimerization and subsequent degradation. Among the proteins phosphorylating FBXW7 are ERK1/2 (Mitogen-Activated Protein Kinase), PLK1/2 (Polo-like kinase 1/2), and CDK5 (cyclin dependent kinase 5). FBXW7 can interact with ERK kinases, resulting in the phosphorylation of FBXW7 at Thr205, which triggers binding to Pin1 (Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1) [120]. Pin1 is known to isomerize specific Ser/Thr-Pro peptide bonds and to regulate their conformational changes [121]. Following binding, Pin1 prevents dimerization of FBXW7, encouraging self-ubiquitination and degradation [5]. A similar method is carried out by PLK proteins. PLK-1 directly phosphorylates FBXW7, leading to self-ubiquitination and degradation. This sets up a regulatory loop, since PLK1 can be transcriptionally activated by c-MYC and N-MY, which are both degradation targets of FBXW7 [122, 123]. Another PLK family member, PLK2, has also been shown to phosphorylate FBXW7, which can lead to uncontrolled centriole duplication [123]. CDK5 is an additional kinase which can negatively regulate FBXW7 through phosphorylation and degradation [124]. Studies have also shown a separate role for CDK5 in priming the microtubule organization protein, NDE1 (NudE Neurodevelopment Protein 1) for degradation by FBXW7 [125]. Altogether these feedback regulatory loops point to a dynamic back and forth between FBXW7 expression, FBXW7 degradation, and the amount of FBXW7 substrates. Not all FBXW7 degradation is mediated through protein phosphorylation. The histone demethylase, LSD1(lysine-specific demethylase 1), also plays a role in controlling FBXW7 activity. Unlike the proteins listed above, which phosphorylate FBXW7, LSD1 binding promotes FBXW7 self-ubiquitylation, leading to both proteasomal and lysosomal degradation of FBXW7 (Fig. 1) [126]. FBXW7 can also be inactivated through mistargeting. Protein kinase C (PKC) specifically phosphorylates the α isoform of FBXW7, which regulates its nuclear localization [127].

FBXW7 protein stability is affected by a balance between ubiquitination (K404 and K412) and interactions with deubiquitinating enzymes (DUB). TRIM25 (tripartite motif-containing 25) is an E3 ligase, which has been shown to ubiquitinate FBXW7 at K412 triggering its proteasomal degradation [128]. However, recent studies suggest that K412 is not sufficient for FBXW7 degradation and that additional TRIP12-mediated branched K11 is required for FBXW7 degradation [129]. DUBs are classical regulators of FBXW7 [130, 131]. One such protease, USP28 (Fig. 1) can bind to multiple structural domains of FBXW7 to inactivate FBXW7 auto-ubiquitination as well as FBXW7-mediated ubiquitination of various targets [130, 132]. USP28 acts in the nucleoplasm and reverses FBXW7α-, but not FBXW7γ-mediated MYC ubiquitination and degradation [132, 133]. In contrast, USP36 promoted de-ubiquitination of MYC in the nucleolus by both FBXW7 isoforms and increased MYC stability [134] (Fig. 1). An additional DUB, USP9X, has been shown to act as a positive regulator of FBXW7 stability by preventing its ubiquitination and degradation. Expectedly, loss of USP9X was associated with poor prognosis in colorectal cancer [135].

A different strategy to inactivate FBXW7 functions relies upon the disruption of the FBXW7/target SCF complex. Some proteins have been shown to interact with FBXW7 while complexed with or without its substrate(s) and therefore prevents subsequent substrate degradation. This is the case for the pseudophosphatase STYX, which binds to the F-box domain of FBXW7 [136]. Without recruitment to the SCF complex, FBXW7 is no longer able to target its substrates for ubiquitination. There are many other factors that can interact with FBXW7
releases these safeguards, facilitating tumor cell proliferation or undergoing cell death. Loss of FBXW7 can prevent the cell cycle from being replicated and allow the cell to arrest and respond to stimuli such as DNA damaging agents to prevent errors at Ser15. This allows for stabilization of p53, release of threonine kinase, ATM stimulates p53 phosphorylation at the G1-S phase transition [146–148]. In response to DNA damage, the serine/threonine kinase, ATM stimulates p53 phosphorylation at Ser15. This allows for stabilization of p53, release of Mdm2, and increased transcription of genes involved in cell cycle arrest. Additional phosphorylation by DNA-PK and GSK3β promotes FBXW7-mediated degradation of p53 to allow the cell cycle to resume after DNA damage has been repaired [149]. Although it is unclear at this time how FBXW7-mediated regulation of p53 may participate in tumorigenesis it is noteworthy that experimental deletion of FBXW7 in murine models of breast cancer is linked to the acquisition of p53 mutations. In concordance, database analyses revealed the co-occurrence of FBXW7 disruption and p53 mutation(s) in breast cancer [150], gastric cancer [151] and high grade serous ovarian cancer [152].

**DNA damage repair and Genome instability**

DNA-damage checkpoint kinase, PLK1 (Polo like kinase-1) plays an essential role in the regulation of DNA replication, regulating pre-replicative complex formation by phosphorylating several proteins [209]. Studies show that FBXW7 can target PLK1 for degradation in response to DNA double strand breaks (DSB) [210]. This event allows transient cell cycle arrest and participation of FBXW7 in DNA repair. Several studies have reported that in response to DSB, FBXW7 binds to PARP (Poly (ADP-Ribose) Polymerase 1) and is rapidly recruited to DNA damage sites [211]. In response to DSBs, ATM is activated and induces phosphorylation of FBXW7 at Ser26 [212]. This promotes the retention of FBXW7 at DSBs, where it interacts with the DNA repair protein, XRCC4 (X-Ray Repair Cross Complementing 4). Unlike traditional targets of FBXW7, XRCC4 is K63 ubiquitinated, an event that facilitates the recruitment of KU80/70 and the initiation of non-homologous end joining (NHEJ) DNA damage repair [212]. FBXW7 has also been involved in other types of DNA repair by regulating degradation of FAAP20, a critical component of the Fanconi anemia (FA) DNA interstrand cross-link (ICL) repair pathway [213]. In addition to DNA repair pathways, FBXW7 plays critical roles during mitosis by acting on multiple targets to ensure proper chromosome segregation and genome stability [214, 215]. Overexpression of Cyclin E, AURKA or PLK1 following the loss of FBXW7 is associated with centrosome duplication and the formation of pseudo-bipolar or multipolar mitotic spindles. The latter is strongly associated with chromosome missegregation, genome instability and aneuploidy. During M phase, AURKA targets a multitude of proteins and plays critical roles in regulating mitotic spindle assembly (SAC), centrosome duplication, chromosome segregation, and cytokinesis. Thus, de-regulation of AURKA, through FBXW7, has implications in genomic stability [206]. As stated above, the kinase, PLK2, can phosphorylates FBXW7 to decrease the stability of FBXW7 [123]. This allows a transient increase in FBXW7-mediated ubiquitination and proteasome degradation control the expression of many proteins with key functions in the regulation of cell cycle progression [117] (Table 4). Many checkpoints are activated in response to stimuli such as DNA damaging agents to prevent errors from being replicated and to allow the cell to arrest and repair damages or undergo cell death. Loss of FBXW7 releases these safeguards, facilitating tumor cell proliferation and accumulation of genetic defects. Some important proteins controlling the G1/S transition of the cell cycle are regulated by FBXW7. These include c-MYC, Cyclin E and p53 [141–143]. c-MYC is generally associated with an increase in the activities of cyclin-dependent kinases, Cdk2, Cdk4 and Cdk6, as well as inhibition of p21WAF/CIP and p27KIP. Thus, inhibition of FBXW7 allows rapid unchecked progression through the G1 to S phase of the cell cycle [144]. The CDK2/Cyclin E complex regulates cell cycle progression by licensing DNA replication at the G1-S phase transition [145]. The inactivation of FBXW7 leads to high levels of c-MYC and Cyclin E and the inability of cells to withdraw from the cell cycle leading to uncontrolled proliferation. Several laboratories have also reported that FBXW7 interacts with and targets p53 for ubiquitination and proteasomal degradation [146–148]. In response to DNA damage, the serine/threonine kinase, ATM stimulates p53 phosphorylation at Ser15. This allows for stabilization of p53, release of
of Cyclin E that is essential for centriole reproduction. In contrast, loss of FBXW7 leads to overexpression of Cyclin E and uncontrolled centriole duplication. FBXW7 also controls the proteolysis of Cyclin E to prevent CENP-A hyperphosphorylation and licenses normal assembly of CENP-A during mitosis. Thus, loss of FBXW7 increases Cyclin E/CDK2-mediated phosphorylation of CENP-A at Ser18 and stimulates chromosomal abnormalities [216]. Furthermore, FBXW7 targets the centriole assembly protein HsSAS6; and FBXW7 inactivation increases HsSAS-6 expression and its recruitment at multiple sites to the mother centriole, leading to supernumerary centrioles [217]. During M phase, AURKA targets a multitude of proteins and plays critical roles in regulating mitotic

### Table 4 Targets of FBXW7

| Factor                  | Description                                           | Expression | References                        |
|-------------------------|-------------------------------------------------------|------------|-----------------------------------|
| SKP1                    | S-phase kinase-associated protein 1                   | ↓          | [136, 153–165]                   |
|                         |                                                       | ↑          | [135, 155, 157, 158]             |
| MYC                     | v-myc avian myelocytomatis viral oncogene homolog     | ↓          | [166]                            |
|                         |                                                       | ↑          | [155, 157, 158]                  |
| CUL1                    | cullin 1                                              | ↓          | [136, 153, 154, 158, 163, 165, 167–173] |
|                         |                                                       | ↑          | [155, 157, 158, 174–177]         |
| CCNE1                   | cyclin E1                                             | ↓          | [126, 162, 163, 165, 172, 178–188] |
| NOTCH1                  | NOTCH 1                                               | ↑          | [126, 163, 164, 180, 189–192]     |
|                         |                                                       | ↑          | [157, 193]                       |
| FBXW7                   | F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase | ↓          | [5, 126, 136, 181, 187, 189]      |
|                         |                                                       | ↑          | [135, 157]                       |
| JUN                     | jun proto-oncogene                                    | ↓          | [188, 191, 194, 195]             |
|                         |                                                       | ↑          | [135]                            |
| MCL1                    | myeloid cell leukemia 1                               | ↓          | [5, 153, 196, 197]               |
| SREBF1                  | sterol regulatory element binding transcription factor 1 | ↓          | [187, 198, 199]                  |
| RBX1                    | ring-box 1, E3 ubiquitin protein ligase               | ↓          | [153, 163, 165]                  |
|                         |                                                       | ↑          | [157, 176]                       |
| STYX                    | serine/threonine/tyrosine interacting protein          | ↓          | [136, 200]                       |
|                         |                                                       | ↑          | [136, 201]                       |
| MED13                   | mediator complex subunit 13                           | ↓          | [169]                            |
|                         |                                                       | ↑          | [155, 157]                       |
| KLF5                    | Kruppel-like factor 5 (intestinal)                    | ↓          | [202]                            |
| MED13L                  | mediator complex subunit 13-like                      | ↓          | [155]                            |
|                         |                                                       | ↑          | [157, 169]                       |
| TPS3                    | tumor protein p53                                      | ↓          | [146]                            |
|                         |                                                       | ↑          | [175, 176]                       |
| MYCBP2                  | MYC binding protein 2, E3 ubiquitin protein ligase    | ↓          | [178]                            |
|                         |                                                       | ↑          | [135, 155, 175, 176]             |
| NFKB2                   | nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p50/p100) | ↓          | [163, 203]                       |
|                         |                                                       | ↑          | [155, 158, 204]                  |
| FBXO45                  | F-box protein 45                                       | ↓          | [157]                            |
|                         |                                                       | ↑          | [155, 157, 175, 176]             |
| MTOX                    | mechanistic target of rapamycin (serine/threonine kinase) | ↓          | [191, 205]                       |
|                         |                                                       | ↑          | [135, 157]                       |
| AURKA                   | aurora kinase A                                       | ↓          | [181, 191, 206]                  |
| HSF1                    | heat shock transcription factor 1                     | ↓          | [155, 207, 208]                  |
|                         |                                                       | ↑          | [155]                            |
| BLM                     | Bloom syndrome, RecQ helicase-like                     | ↓          | [194]                            |

List of the most common, experimentally verified, FBXW7 targets degraded by ubiquitination (https://thebiogrid.org). According to the available literature, FBXW7 can either up- or down-regulate the expression of the listed target proteins. Some cellular targets can be up-regulated and down-regulated in different cancer types or under distinct physiological conditions. References for studies which describe target degradation is listed on the right-end side.
spindle assembly (SAC), centrosome duplication, chromosomes segregation and cytokinesis [218]. All these studies clearly demonstrate why loss of FBXW7 has far-reaching implications for unchecked proliferation of tumor cells, chromosome instability, and carcinogenesis.

**Regulation of cell survival**

Consistent with its tumor suppressor functions, FBXW7 is generally an inducer of apoptosis, and its loss of function promotes increased survival and resistance to apoptotic signals. FBXW7 promotes ubiquitination and degradation of myeloid leukemia 1 (MCL-1) a member of the pro-survival Bcl-2 family regulating apoptosis in tumor cells [219, 220]. MCL-1 has a high affinity for pro-apoptotic Bcl-2 family members, Bax, Bak, Bim, Bid, Puma and Noxa compared to other Bcl-2 pro-survival family members, suggesting that MCL-1 is an essential sentinel against pro-apoptotic signals. Upregulated expression of MCL-1 following the loss of FBXW7 has been described in many cancer types and shown to correlate with increased resistance of tumor cells to various therapies. FBXW7 also regulates YAP (Yes-associated protein), a negatively regulated downstream effector of the Hippo signaling pathway that plays an important role in inhibiting apoptosis [221]. Clinical studies have demonstrated that YAP is overexpressed in tumors and associated with poor survival due to resistance to apoptosis [222]. Consistent with the fact that FBXW7 targets YAP for degradation [223], a direct correlation between the loss of FBXW7 and high expression of YAP has been demonstrated in HCC, gastric cancer (GC), and pancreatic cancers [224–226]. In addition, increased expression of YAP can stimulate transcription of SOX9 a transcription factor degraded by FBXW7 in response to DNA damage caused by cytotoxic drugs or UV-irradiation [227]. In the absence of FBXW7, high levels of SOX9 favor cell survival and accumulation of genetic defects [228]. FBXW7 also plays roles in other forms of cellular death. Ferroptosis is an iron-dependent form of non-apoptotic cell death, which is triggered by the oncogenic RAS selective lethal small molecule erastin [117, 229]. FBXW7 can trigger ferroptosis by inhibiting the expression of stearoyl coenzyme A desaturase (SCD1) through the inhibition of nuclear receptor subfamily 4 group A member 1 (NR4A1), which regulates lipid peroxidation and promotes ferroptosis [120, 230].

**Role of FBXW7 in the tumor microenvironment and tumor immunity**

Tumor cells can functionally shape the immune microenvironment required for their proliferation [231]. In cancer, FBXW7 can inhibit macrophage M2-type polarization by mediating c-MYC degradation. M2-type macrophages are a pro-oncogenic phenotype that promotes angiogenesis by enhancing the invasive properties of tumor cells, remodeling the extracellular invasive matrix, and favoring tumor cell proliferation. FBXW7 inhibits the direction of macrophage M2-type polarization by inhibiting the tumor immune microenvironment thereby affecting cancer progression [232]. FBXW7 also modulates the tumor immune microenvironment by mediating the degradation of C/EBPδ, thereby inhibiting Toll-like receptor 4 expression, reducing inflammation, and modulating the innate immune response of macrophages to pathogens [233]. The tumor microenvironment can also be altered through the process of epithelial mesenchymal transition (EMT), a process by which epithelial cells are transformed into migratory and invasive cells [234]. EMT leads to the spread of individual cancer cells from the primary tumor site, participates in the dedifferentiation process leading to malignant cancer, and increases the malignancy of the tumor [235]. Several proteins regulated by FBXW7 influence EMT such as EMT transcription factors (EMT-TFs), including mTOR, SnaI, c-MYC [236, 237], SOX9 [227, 238], and ZEB2 [100]. Studies have also shown that CCL2 (C-C Motif Chemokine Ligand 2) activation promotes metastatic ecotone formation through recruitment of monocyte myeloid-derived suppressor cells and macrophages [239, 240]. FBXW7 can inhibit CCL2 gene transcriptional activation by negatively regulating NOTCH expression levels; and inhibition of CCL2/CCR2 signaling has been shown to suppress tumor metastasis demonstrating an important role of the FBXW7/NOTCH/CCL2 axis in the regulation of cancer metastasis [241]. In addition, FBXW7 was found to control CCL2 expression by stimulating ubiquitination of EZH2 (enhancer of zeste homolog 2); thereby reducing global H3K27me3 on the promoter of CCL2 [242]. FBXW7 has also been shown to control innate immunity signaling pathways. Loss of FBXW7 has been associated with a reduced ability of cells to activate double strand RNA (dsRNA) and interferon (IFN) responses normally activated in cells infected with tumor RNA viruses. Impairment in sensing dsRNA in FBXW7 deficient cells was associated with a loss of MDA5 (Interferon Induced with Helicase C Domain 1) and RIG-I (Retinoic Acid-Inducible Gene 1 Protein) expression and associated with resistance to anti-PD-1 therapies [105]. In addition, loss of FBXW7-mediated proteasomal degradation of IFN-γ receptor 1 (IFNGR1) results in the constitutive activation of IFNGR1 signaling. Activated IFNGR1 stimulates the recruitment of immune suppressive neutrophils to the tumor site, facilitating tumor growth and metastasis formation in patients with triple negative breast cancer (TNBC) [243].
Targeting FBXW7: Development of novel therapeutic strategies.

As detailed above, activation of specific signaling pathways that promote tumor cell proliferation, cell cycle progression, or oncogenesis, such as Erk1/2, Pin1 and PLK1, have been associated with FBXW7 auto-ubiquitination and degradation. In turn, loss of FBXW7 expression is associated with a reduced turnover of downstream targets. This results in the accumulation of specific oncoproteins and oncoprotein dependencies that can create an opportunity for targeted therapies in tumor cells. Several strategies are worth pursuing in targeting cancers dependent on FBXW7 loss of function(s): 1- targeting the reactivation of FBXW7 expression in the case of tumors with wild type FBXW7 that is inactivated through epigenetic mechanisms, or 2- targeting downstream effectors of FBXW7 inactivation in case of gene mutation or deletion.

Restoration of FBXW7 tumor suppressor functions to increase drug sensitivity

Overexpression of wild-type FBXW7 can restore the ability to ubiquitinate target proteins in cells not expressing FBXW7. This suggests that the drug resistance problem caused by FBXW7 loss may be reversible. As discussed previously, numerous studies have demonstrated the clinical significance of FBXW7 promoter hypermethylation in carcinogenesis [20–22]. Inhibition of DNA methyltransferases by decitabine has been used in various preclinical and clinical settings with promising results. Regarding FBXW7, a recent study showed that both, in vitro lung cancer cells and in vivo lung cancer xenograft mouse models treated with decitabine revert the FBXW7 promoter to an unmethylated state. This resulted in increased expression of FBXW7 followed by decreased expression of MCL-1. Consequently, use of the Bcl-2 inhibitor, Venetoclax, and decitabine demonstrated strong synergistic toxicity against lung cancer cells [244]. NSCLC cells with low expression of FBXW7 are resistant to microtubule targeting agents including Taxol. However, NSCLC cells with loss of FBXW7 are highly sensitive to class 1 histone deacetylase (HDAC) inhibitor, Entinostat MS-275. In addition, Taxol resistance was effectively overcome by MS-275 treatment, suggesting that HDAC inhibitors may have therapeutic benefits in the treatment of aggressive Taxol-resistant NSCLCs that have loss of FBXW7 expression [245]. Similar results were also published on hematological cancer cells harboring FBXW7 inactivating mutations [246]. In a preclinical study, the histone deacetylase inhibitor, Belo-daq (belinostat) also inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture [247]. The downfall of using these therapies to treat cancer, is that DNA methyltransferases drugs have a global impact on cellular gene expression. While FBXW7 has the potential to be re-activated, so would addition hypermethylated genes, which may include repressed oncogenes. This could potentially be overcome if FBXW7 could be specifically targeted with gene editing technology.

Another route to restore FBXW7 expression may be to target FBXW7-microRNAs in tumor cells that harbor wild-type FBXW7 mRNA. Studies performed in vitro and in animal models have shown several promising approaches including LNA-antimiRs or small molecule inhibitors of miRNAs (SMIR), which prevent miRNA-target interaction(s). Some of these are developed by Regulus Therapeutics and are currently in clinical trials for the treatment of HCV cancer [248]. One potential issue may be related to the unintended side effect of miRNAs, since each miRNA has dozens of gene targets. With the development of quantum computing, highly complex networks may be solved and offer clarity for the best approach to inactivate selected miRNAs in cancers.

In some instances, cancers cells express low levels of FBXW7 protein because of pathologic rapid turnover. This can readily be observed in cells with hyperactivation of ERK1/2 signaling or high activity of PLK1 or Pin1. Specific small inhibitors for these pathways can restore FBXW7 expression and/or induce cell cycle arrest or apoptosis. These inhibitors, PLK1 inhibitor onvansertib and Pin1 inhibitor sulfopin, are currently being tested in clinical trials [249, 250]. While there is no specific ERK1 inhibitor currently approved by the FDA, there are several inhibitors targeting the upstream kinase MEK1 (Ben-imetinib, Cobimetinib, Selumetinib and Tremetinib). In addition to FBXW7 self-ubiquitination, studies have shown that in melanoma cells the nuclear accumulation of MDM2 leads to MDM2-dependent ubiquitination and rapid downregulation of FBXW7 resulting in upregulation of FBXW7-degraded oncoproteins such as p63 [251, 252]. Although melanoma cells are highly resistant to MAPK inhibitors, a combination with MDM2 inhibitor, Nutlin-3A, resulted in elevated FBXW7 expression, p63 degradation, and apoptosis of melanoma cells effectively reversing MAPK inhibitor resistance [253].

Targeting downstream effectors activated in FBXW7 negative tumors

Several studies have shown that deletion of FBXW7 can lead to targeted therapy resistance by stabilizing MCL-1 [153, 254]. Heat shock protein 90 (Hsp90) is an oncoprotein that is widely expressed in cancers and acts to promote malignant progression of tumors that can be inhibited by Hsp90 inhibitors [255, 256]. However, the sensitivity of Hsp90 inhibitors is limited by the level...
of MCL-1, which is overexpressed in some cancers due to FBXW7 mutations [107]. This makes the efficacy of Hsp90 inhibitors limited. However, the sensitivity of cancer cells to Hsp90 inhibitors can be restored following inhibition of MCL-1 [257, 258]. In this regard, FBXW7 mutations could be proposed as resistance markers for Hsp90 inhibitor targeting [259]. Somatic FBXW7 mutations in squamous cell carcinoma (SCC) are associated with stabilized MCL-1 and high Bim levels [260]. This results in a poor response to standard chemotherapy but a robust response to HDAC inhibitors and enhanced synergy with the combination Vorinostat/ABT-737. As described above, PLK1 stimulates phosphorylation and degradation of FBXW7. The use of PLK1 inhibitors to induce toxicity in tumor cells with loss of FBXW7 has been reported in many studies. Investigations demonstrate that a combination of PLK1 (BI2536) and Bcl-2 (ABT199) inhibitors synergized and induced apoptosis in FBXW7 low, and c-MYC overexpressing, tumor cells [122]. Several AURKA inhibitors, another target of FBXW7, have also shown promising results in vitro and in preclinical studies and several inhibitors have progressed to phase II/III clinical trials [261, 262].

**Targeting tumors carrying mutated inactive FBXW7**

To date, there are no reports of any specific drugs directly targeting FBXW7. DrugBank uses the DNA sequence of FBXW7 as a starting point, applying the target-drug match-related function of FBXW7, which allows querying the potentially effective inducers of FBXW7 (Table 5). The DrugBank platform showed that there are 14 drugs that may bind to bases 148878 to 148938 of FBXW7, which can act as an inducer with FBXW7. Whether these drugs may be effective in targeting cells with loss of FBXW7 remains to be investigated.

There is limited data on studies aimed at targeting cells with mutated FBXW7. Metastatic unresectable malignant melanoma (MM) is inherently characterized by poor radiotherapy results. The combination of FDA-approved mTOR inhibitors, Everolimus and Temozolomide, has significant therapeutic effects and improved survival in advanced MM patients carrying FBXW7 mutations [263]. In xenograft mouse models of lung cancer, cells harboring FBXW7 R465H were particularly sensitive to treatment with the mTOR inhibitor, Torisel (tansigrolimus) [264]. A preclinical study also showed that breast cancer cells with mutated FBXW7 have increased sensitivity to the mTOR inhibitor, Rapamune (Sirolimus) [265]; and phase 1 studies demonstrated prolonged and stable disease in a patient with hepatocellular fibrolamellar carcinoma harboring FBXW7 E192A treated with Rapamune [266]. Tumor cell lines with deletions or mutations in FBXW7 were particularly sensitive to rapamycin treatment suggesting that loss of FBXW7 may serve as biomarker for an increased susceptibility to inhibitors of the mTOR pathway [267]. A study reported that FBXW7-associated drug resistance is reversed by induction of terminal differentiation in murine intestinal organoid culture. Further results support the hypothesis that a differentiating therapy may successfully target FBXW7-mutated CRC cells [265]. However, it appears that no follow up studies have been published in the area.

**Table 5** FBXW7 potential inducers

| Combining regions | Drug                  | Drug Research Phase | Drug Investigation Phase | Action   |
|-------------------|-----------------------|---------------------|--------------------------|----------|
| 148878-148938     | Troleandomycin        | approved            |                          | inducer  |
|                   | Dexamethasone         | approved, investigational, vet_approved | inducer |
|                   | Rifampicin           | approved            |                          | inducer  |
|                   | Midostaurin           | approved, investigational | inducer |
|                   | Dexamethasone acetate| approved, investigational, vet_approved | inducer |
|                   | Myrrh                 | approved            |                          | inducer  |
|                   | Brigatinib            | approved, investigational | inducer |
|                   | Rifapentine           | approved, investigational | inducer |
|                   | Prednisone            | approved, vet_approved | inducer |
|                   | Methylprednisolone    | approved, vet_approved | inducer |
|                   | Lemborexant           | approved, investigational | inhibitor/inducer |
|                   | Prednisolone phosphate| approved, vet_approved | inducer |
|                   | Relugolix             | approved, investigational | inducer |
|                   | Ursodeoxycholic acid  | approved, investigational | inducer |

Potential inducers for FBXW7 based on DrugBank database prediction tool, screened based on the sequences of FBXW7 in GeneBank. According to the database, “The term “inducer” can be a drug or chemical that typically serves to induce or trigger the appropriate gene transcription necessary to synthesize new copies of a particular enzyme, in addition to what quantity may already be present for that enzyme in the body” (https://www.drugbank.com/)
Tumor mutation profiling can reveal co-occurring mutations and an opportunity to distinguish between favorable and unfavorable gene profiles in response to specific chemotherapy or targeted therapies ensuring maximum patient benefits from treatment [268]. In a clinical study of therapies for solid tumors with PIK3CA mutations, in which co-occurring mutations such as the FBXW7 mutation were also detected, the investigators uniquely found that Alpelisib (BYL719) selectively inhibited PI3Kα in solid tumors with PIK3CA mutations containing the FBXW7 co-occurring mutation, effectively inhibiting tumor growth and improving patient survival [269]. In another clinical trial, LY3039478 treatment resulted in a partial response that lasted 9.5 months in a patient with Erbb2 (Her2)-negative breast cancer cells with a FBXW7 mutation. In a preclinical study, the combination treatment of JQ1 and Ulixertinib (BVD-523) or PLX8394 resulted in greater decreased proliferation of HTLV-1 ATL cells with loss of function FBXW7 mutant S462P when compared to treatment with JQ1 alone [86]. Studies have shown that loss of FBXW7-mediated degradation of sterol regulatory element binding protein 1 (SREBP1) is associated with an increased expression of the IDH1 (Isocitrate Dehydrogenase (NADP(+) 1) gene. Mutations in IDH1 can lead to downstream tumorigenic effects that alter histone and DNA methylation activities. Interestingly, the loss of FBXW7 and the presence of mutated IDH1 drastically increases radiation sensitivity of tumor cells. Therefore, co-occurrence of FBXW7 mutations (such as R505 or R465) along with mutated IDH1 may harbor a favorable prognosis [270].

Conclusion

In summary FBXW7 is implicated in essential pro-survival signaling pathways and exhibits an inextricable link to cancer progression. In fact, FBXW7 is frequently inactivated or mutated in human cancers and inactivating mutations have been associated with resistance to therapies and poor prognosis for patients. Important challenges in studying FBXW7 remain due to the large number of cellular targets with different levels of binding affinity and the complex regulation of FBXW7 expression and its functions. For these reasons observations are often cell type specific and may not be generalized. Additionally, heterogeneity within tumors may further complicate interpretations of studies aimed to understand signaling pathways affected by FBXW7 inactivation. Another limitation is that reactivation of FBXW7 tumor suppressor functions, through gene editing or gene transfer therapy, is not easily feasible in vivo. However, the wide range of pro-oncogenic targets makes FBXW7 highly valuable for therapeutic targeting. Targeted therapies may offer new alternative treatments by taking advantage of FBXW7 mutations and specifically targeting tumor cells. Future studies will determine if targeting FBXW7 solely or using dual therapies that target FBXW7 and/or downstream or parallel pathways, is more beneficial to cancer treatment. The latter may prove more advantageous, as complete ablation of FBXW7 expression in combination with specific anti-cancer treatments, has been shown to desensitize cancer cells to death. This suggests that some FBXW7 activity may be required and that a reduction, but not complete loss, of FBXW7 activities may provide stronger anti-cancer therapy. By targeting FBXW7 indirectly, drug resistance may be relieved and allow for restoration of current drug therapies to work more efficiently. Future studies aimed to reactivate FBXW7 functions may take advantage of the fact that for the most part tumor cells are heterozygous and harbor both wild type and mutated copies. Since mutated FBXW7 has a dominant negative effect, it is possible to design or screen for small molecules that would selectively interact with mutated FBXW7 and disrupt dimerization. This approach may in theory sequester mutated FBXW7 freeing wild type FBXW7 protein to perform its tumor suppressor functions. Another possibility, and of special interest for future studies, is the search for the presence of neoantigens in mutated FBXW7, which may help develop novel cancer immunotherapies targeting cancer cells carrying specific mutations.

Abbreviations

ATM: Ataxia-Telangiectasia Mutated; CEBP: CCAAT/enhancer-binding protein-δ; CDK: Cyclin dependent kinase; ceRNA: Competing endogenous RNA; CRC: Colorectal carcinoma; CSN6: Signalosome subunit 6; DSB: DNA double strand breaks; DUB: Deubiquitinating enzymes; EMT: Epithelial-mesenchymal transition; ERK: Extracellular signal-regulated kinase; GC: Gastric cancer; GSCs: Gloma stem-like cells; HCC: Hepatocellular carcinoma; HSAS-6: Human spindle assembly abnormal 6; MEK: Mitogen-activated protein kinase; METTL: Methyltransferase-like; miRNAs: MicroRNAs; ncRNAs: Non-coding RNAs; NSCLC: Non-small cell lung cancer; PKC: Protein kinase C; PLK1: Polo like kinase-1; PRMT5: Protein arginine methyltransferase 5; Raf: Rapidly accelerated fiбросарcoma; Ras: Rat sarcoma virus; SCD1: Stearoyl coenzyme A desaturase; SREBP: Sterol Regulatory Element-Binding Protein; STAT3: Signal Transducer and Activator of Transcription 3; TNBC: Triple-negative breast cancer; WTAP: WilmsTumour 1-Associating Protein; XRCC4: X-Ray Repair Cross Complementing 4.

Acknowledgements

The authors would like to thank Brandi Miller for editorial assistance.

Authors’ contributions

Jingyi Fan, Marcia Bellon, Mingyi Ju, Lin Zhao, and Minjie Wei researched materials, made the figures and wrote the manuscript. Liliwu Fu and Christophe Nicot analyzed and wrote the manuscript.

Authors’ information

Jingyi Fan: Graduate student. State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute; Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122.
Liaoning Province, China Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, Liaoning Province, China.

Marcia Bellon: Ph. D, Senior Scientist. Department of Pathology and Laboratory Medicine, Center for Viral Pathogenesis, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

Mingyi Ju. Graduate student. Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122.

Liaoning Province, China Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, Liaoning Province, China.

Lin Zhao. Ph.D. Professor. Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122.

Liaoning Province, China Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, Liaoning Province, China.

Christophe Nicot. Ph. D Professor, Department of Pathology and Laboratory Medicine, Center for Viral Pathogenesis, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

Funding
This work was supported by grant R01CA201309 to Christophe Nicot.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Molecular Cancer.

Declarations
Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
Authors declare no financial conflict of interest. Dr. Nicot is an editorial board member of

Author details
1 State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute; Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China. 2 Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China. 3 Liaoning Province, China Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang 110122, Liaoning Province, China. 4 Department of Pathology and Laboratory Medicine, Center for Viral Pathogenesis, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.

Received: 22 November 2021 Accepted: 22 February 2022 Published online: 26 March 2022

References
1. Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17:115–33.

2. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 2004;101:9985–90.

3. Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, Leighty R, et al. The tumor suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J. 2010;29:4106–17.

4. Pelorosso FG, Balman A. C/EBPdelta: friend or foe? a novel role for C/EBPdelta in metastasis. EMBO J. 2010;29:4063–5.

5. Min SH, Lau AW, Lee TH, Inuzuka H, Wei S, Huang P, et al. Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell. 2012;46:771–83.

6. Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, et al. Prolifer-isomerine P11 controls normal and cancer stem cells of the breast. EMBO Mol Med. 2014;6:199–11.

7. Wu JO, Perez-Losada J, DiW, DelRosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A. Fbw7/Cdc4 is a p53-dependent, hsp90/supracompressor suppressor gene. Nature. 2004;423:775–9.

8. Jiang X, Xing H, Kim TM, Jung Y, Huang W, Yang H, et al. Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. Stem Cells. 2012;30:1313–26.

9. Welcker M, Larinore EA, Frapper L, Clurman BE. Nuclear targeting of the fwb7 ubiquitin ligase by a pseudosubstrate and glycogen synthase synacthe kinase 3. Mol Cell Biol. 2011;31:1214–24.

10. Clairmont CS, Sarangi P, Ponniesenkel K, Galli LD, Csete I, Moreau L, et al. TRP13 regulates DNA repair pathway choice through REV7-conformational change. Nat Cell Biol. 2020;22:87–96.

11. Hellmuth S, Gomez HL, Pendas AM, Stemmann O. Securin-independent regulation of separase by checkpoint-induced shugoshin-MAD2. Nature. 2020;580:336–41.

12. Zhang G, Zhu Q, Fu G, Hou J, Hu X, Cao J, et al. TRP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/C-MYC axis. Br J Cancer. 2019;121:1069–78.

13. Liu R, Gao J, Yang Y, Qiu R, Zheng Y, Huang W, et al. PhD finger protein 1 (PHF1) is a novel reader for histone H4R3 symmetric dimethylation and coordinates with PRMT5-WDR77/CRL4B complex to promote tumori-genesis. Nucleic Acids Res. 2018;46:6608–26.

14. Sancho R, Blake SM, Tendeng C, Clurman BE, Lewis J, Behrens A. Fbw7 repression by hes5 creates a feedback loop that modulates Notch-mediated intestinal and neural stem cell fate decisions. PLoS Biol. 2013;11:e1001586.

15. Chen L, Hu B, Han Z, Liu W, Zhu J, Chen X, et al. Repression of FBXW7 by HESS contributes to inactivation of the TGF-beta signaling pathway and alleviation of endometriosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2021;35:e20938.

16. Matsumoto M, Fushita M, Ohtsuki Y. Posttranslational phosphoryla-
tion of mutant p53 protein in tumor development. Med Mol Morphol. 2006;39:79–87.

17. Ningning Li FL, Kalakouti E, Normatova M, Babaei-Jadidi R, Tomlinson I, Nateri AS. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15. Oncotarget. 2015;6:9240–55.

18. Jones PAL, Peter W. Cancer epigenetics comes of age. Nat Genet. 1999;21:163–9.

19. Akhoondi S, Lindstrom L, Widschwendter M, Corcoran M, Bergh J, Spruck C, et al. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res. 2010;12:R105.

20. Gu Z, Mitsui H, Inomata K, Honda M, Endo C, Sakurada A, et al. The methylation status of FBXW7 beta-form correlates with histological
subtype in human thymoma. Biochem Biophys Res Commun. 2008;357:685–8.

20. Molnar B, Gyalambó O, Peterfi B, Wichmann B, Csabai I, Bodor A, Kalmar A, Szigeti KA, Bartak BK, Nagy ZB, Valcz G, Patai AV, Igaz P, Tulassa ZJ. Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations. BMC Cancer. 2018;18:695–708.

21. Lindstrom L, Akhoondi S, Widschwendter M, Corcoran M, Bergh J, Majumder S, Alinari L, Roy S, Miller T, Datta J, Sif S, et al. Methylation of histone H3 and H4 by PRMT5 regulates ribosomal RNA gene transcription. J Cell Biochem. 2010;109:553–63.

22. Chatterjee B, Ghosh K, Kanade SR. Reversatrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21(CIP1) in human breast cancer cell lines. Biofactors. 2019;45:818–29.

23. Qin Y, Hu Q, Xu J, Si S, Dai W, Liu W, Wu S, Sun Q, Zhang Z, Qi N, Zhang B, Yu X, Xu K. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/mCyc axis. Cell Commun Signal. 2019;17:30–44.

24. Chen Y, Lin Y, Shu Y, He J, Gao W. Interaction between N6-methyladenosine (m6A) modification and noncoding RNAs in cancer. Mol Cancer. 2020;19:194–1107.

25. Wu Y, Chang N, Zhang Y, Zhang X, Lu Y, Che Y, Qiao T, Wu B, Zhou Y, Jiang X, Jiang Z, Zhang J. METTL3-mediated m6A modification of FBXW7 suppresses lung adenocarcinoma. J Exp Clin Cancer Res. 2020;40:90–104.

26. Huang H, Yu X, Han X, Hao J, Zhao J, Bebek G, Bao S, Prayson RA, Khalil AM, Jankowsky E, Yu JS. Piwi1 Regulates Glioma Stem Cell Maintenance and Glioblastoma Progression. Cell Rep. 2021;34:108522–49.

27. Xia W, Zhou J, Luo H, Liu Y, Peng C, Zheng W, Ma W. MicroRNA-32 promotes cell proliferation, migration and suppresses apoptosis in breast cancer cells by targeting FBXW7. Cancer Cell Int. 2017;17:14–24.

28. Zhao C, Shen L, Mao L, Wang B, Li Y, Hu H. miR-92a-3p is upregulated in cervical cancer and promotes cell proliferation and invasion by targeting FBXW7. Biochem Biophys Res Commun. 2015;458:63–9.

29. Zhang G, Li S, Tu J, Ge Y, Wang Q, Ma G, Zhao Q, Wu D, Gong W, Du M, Chu H, Wang M, Zhang A, Zhang Z. LncRNA MT1P functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer. Mol Cancer. 2018;17:87–97.

30. Li Y, Wang J, Ma Y, Du W, Feng K, Wang S. miR-101-loaded exosomes secreted by bone marrow mesenchymal stem cells requires the FBXW7/HIF1alpox/FoxP3 axis, facilitating osteogenic differentiation. J Cell Physiol. 2021;236:4258–72.

31. Tian X, Liu Y, Wang Z, Wu S. miR-144 delivered by nasopharyngeal carcinoma-derived EVs stimulates angiogenesis through the FBXW7/HIF-1alpox/VEGF-A axis. Mol Ther Nucleic Acids. 2021;24:1000–11.

32. Wang Y, Cao S, Li J, Li M, Ni H, Tian Y. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function. Am J Cancer Res. 2016;6:2561–75.

33. Tang B, Lei B, Qi G, Liang X, Tang F, Yuan S, Wang Z, Yu S, He S. MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression. J Exp Clin Cancer Res. 2016;35:93–104.

34. Chiang CH, Chu PY, Hou MF, Hung WC. MiR-182 promotes proliferation and invasion and elevates the HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7. Am J Cancer Res. 2016;6(8):1785–98.

35. Li L, Sarver AL, Khatri R, Hajeri PB, Karnem. I, French AJ, et al. Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma. J Pathol. 2016;234:498–501.

36. Sun D, Wang G, Xiao C, Xin Y, Hsa_circ_001988 attenuates GC progression in vitro and in vivo via sponging miR-197-3p. J Cell Physiol. 2021;236:612–24.

37. Eko K, Iwatsuki M, Watanabe M, Ishimoto T, Ida S, Immamura Y, et al. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/ FBXW7 pathway. Int J Cancer. 2015;136:1373–47.

38. Xu Y, Sengupta T, Krukera L, Minella AC. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem. 2010;285:34349–46.

39. Xu J, Wu W, Wang J, Huang C, Wen W, Zhao F, et al. miR-367 promotes the proliferation and invasion of non-small cell lung cancer via targeting FBXW7. Oncol Rep. 2017;37:1052–6.

40. Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang D, Dou C, Yu M, Liu Q, Tu K. Long non-coding RNA CAS2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CAS2/miR-367/ FBXW7 axis. Mol Cancer. 2017;16:123–37.

41. Lin H, Zhang L, Zhang C, Liu P. Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer. J Cell Mol Med. 2020;24:8980–41.

42. Zhang P, Cao L, Fan P, Mei W, Wu M. LncRNA-MI-F: a c-Myc-activated long non-coding RNA, suppresses glycosylation by promoting Fbxw7-mediated c-Myc degradation. EMBO Rep. 2016;17:1204–20.
63. Chen H, Ali M, Ruben A, Stelmakh D, Pak M. E2F6-Mediated Down-regulation of miR22HG Facilitates the Progression of Laryngocarcinoma by Targeting the miR-3000-3p/FBXW7 Axis. Mol Cell Biol. 2020;40(10):e00496-514.
64. Lin C, Zhang S, Wang Y, Wang Y, Nice E, Guo C, et al. Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis. Clin Cancer Res. 2018;24:486–98.
65. Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, et al. Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. J Natl Cancer Inst. 2018;110(3):304–18.
66. Lu H, Yao B, Wen X, Jia B. FBXW7 circular RNA regulates proliferation, migration and invasion of colorectal carcinoma through NEK2, mTOR, and PTEN signaling pathways in vitro and in vivo. BMC Cancer. 2019;19:189–25.
67. Jeon Tl, Esquejo RM, Roqueta-Rivera M, Phelan PE, Moon YA, Govindarajan SS, et al. An SHREB-responsive microRNA operon contributes to a regulatory loop for intracellular lipid homeostasis. Cell Metab. 2013;18:51–61.
68. Liu S, Liu H, Deng M, Wang H. miR-182 promotes glioma progression by targeting FBXW7. J Neurol Neurosci. 2020;411:11689–94.
69. Murugesan M, Premkumar K. Integrative miRNA-mRNA functional analysis identifies mir-182 as a potential prognostic biomarker in breast cancer. Mol Oncol. 2021;15:433–43.
70. Chen S, Shen X. Long noncoding RNAs: functions and mechanisms in colon cancer. Mol Cancer. 2020;19:167.
71. Su X, Jing J, Wang Z, Chen L, Cui M, Jiang B. microRNAs and ceRNAs: RNA networks in pathogenicity of cancer. Chin. J Cancer Res. 2013;25:235–9.
72. Miao S, Wang J, Xuan L, Liu X. LncRNA TTN-AS1 acts as sponge for miR-15b-5p to regulate FBXW7 expression in ovarian cancer. BioFactors. 2020;46:600–7.
73. Li S, Mei Z, Hu HB, Zhang X. The IncRNA MALAT1 contributes to non-small lung cancer development via modulating miR-124/SAT3 axis. J Cell Physiol. 2018;233:6679–88.
74. Huo W, Qi F, Wang K. Long non-coding RNA FER1L4 inhibits prostate cancer progression via sponging mir-92a-3p and upregulation of FBXW7. Cancer Cell Int. 2020;20:64–76.
75. Lv Z, Zhang Y, Xu L, Lin Y, Ge Y. RETRACTED: The function of long non-coding RNA MT1JP in the development and progression of gastric cancer. Pathol Res Pract. 2018;214:1218–23.
76. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res. 2013;73:5609–12.
77. Ye F, Gao G, Zou Y, Zheng S, Zhang L, Ou L, et al. circFBXW7 Inhibits Malignant Progression by Sponging miR-197-3p and Encoding a 185-aa Protein in Triple-Negative Breast Cancer. Mol Ther Nucleic Acids. 2018;13:265–74.
78. Forbes SA, Beare D, Boutselakis H, Bamford S, Binda T, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D773–83.
79. Davis RJ, Velcker M, Clurman BE. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell. 2014;26:655–64.
80. Ikenoue T, Terakado Y, Zhu C, Liu X, Ohsumi T, Matsubara D, Fujii T, Kakuta H, et al. An SREBP-responsive microRNA operon contributes targeting FBXW7. J Neurol Sci. 2020;411:116689–94.
104. Liu H, Wang K, Fu H, Song J. Low expression of the ubiquitin ligase FBXW7 correlates with poor prognosis of patients with colorectal cancer. J Cell. Exp Pathol. 2018;11(1):413–19.

105. Gatkhalder C, Liu D, Miao D, Lutterbach B, DeVine AL, Lin C, et al. Inactivation of FBXW7 Impairs dsRNA Sensing and Confers Resistance to PD-1 blockade. Cancer Discov. 2020;10:1296–311.

106. Wang HP, Chen WJ, Shen JM, Ye T, Xie HW. Attenuating glucose metabolism by FBXW7 promotes Taxol sensitivity of colon cancer cells through downregulating NADPH oxidase 1 (Nox1). Ann Transl Med. 2021;9:8886.

107. Tong J, Tan S, Zou F, Yu J, Zhang L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking McI-1 degradation. Oncogene. 2017;36:787–96.

108. Tong J, Wang P, Tan S, Chen D, Nikolovska-Coleska Z, Zou F, Zhang L, et al. McI-1 Degradation Is Required For Targeted Therapeutics to Eradiate Colon Cancer Cells. Cancer Res. 2017;77(9):5212–21.

109. Izumi D, Ishimoto T, Miyake K, Eto T, Anima K, Kiyozumi Y, et al. Colorectal tumor suppressor. Semin Cancer Biol. 2020;67:1–15.

110. Gonzalez-Bosquet J, Bakkum-Gamez JN, Weaver AL, McGree ME, Wu J, Tan Y, Sun D, Jiang W, Klotz-Noack K, Vashisht AA, Wohlschlegel J, et al. Watanabe T, Nanamiya H, Kojima M, Nomura S, Furukawa S, Soeda S, et al. Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradiate Colon Cancer Cells. Cancer Res. 2017;77(9):2512–21.

111. Maskey D, Marlin MC, Kim S, Kim S, Ong EC, Li G, et al. Cell cycle-cancer, Int. J Clin Exp Pathol. 2018;11(1):413–19.

112. Gonzalez-Bosquet J, Bakkum-Gamez JN, Weaver AL, McGree ME, Wu J, Tan Y, Sun D, Jiang W, Klotz-Noack K, Vashisht AA, Wohlschlegel J, et al. Watanabe T, Nanamiya H, Kojima M, Nomura S, Furukawa S, Soeda S, et al. Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradiate Colon Cancer Cells. Cancer Res. 2017;77(9):2512–21.

113. Popov N, Wanzel M, Madireddy M, Zhang D, Beijersbergen R, Bernards R, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol. 2007;9:765–74.

114. Sun XX, He X, Yin L, Komada M, Sears RC, Dai MS. The nuclear ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. Proc Natl Acad Sci U S A. 2015;112:3734–9.

115. Khan OM, Carvalho J, Spencer-Dene B, Mitter R, Frith D, Snijders AP, et al. The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal cancer. J Clin Invest. 2018;128:1326–37.

116. Reiterer V, Figueras-Puig C, Le Guerroue F, Confalonieri S, Vecchi M, Jalapothu D, et al. The pseudophosphatase STYX targets the F-box of Fbw7 modulates substrate degradation and activity. FEBS Lett. 2020;594:7067–73.

117. Cizmecioglu O, Krause A, Bahtz R, Ehret L, Malek N, Hoffmann J, Piorkowski MD, van den Maas J, de Vries LS, van Dam J, et al. Blockade. Cancer Discov. 2020;10:1296–311.

118. Zhang Q, Li X, Cui K, Liu C, Wu M, Prochownik EV, et al. The MAPK3–TRIM25–FBXW7 axis affects c-Myc protein stability and tumor development. Cell Death Differ. 2020;27:420–33.

119. Dangles-Marie M, Cacheux W, Rouleau E, Lazartigues J, Girard E, Briaux A, Mariani P, Richon S, Vacher S, Buecher B, Richard-Molard M, Jeannot E, Servant N, Parkinson D, Mariotte S, Irie Y, Irie A. Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. Oncotarget. 2017;8(1):464–76.

120. Cremona CA, Sancho R, Diefenbacher ME, Behrens A, FBW7 and its counteracting forces in stem cells and cancer. Oncoproteins in the balance. Semin Cancer Biol. 2016;36:52–61.

121. Buckley SM, Aranda-Orgilles B, Strikoudis A, Apostolou E, Loizou E, Moran-Crusio K, et al. Regulation of p53 and protein stability. Cell Stem Cell. 2012;11:783–98.

122. Diefenbacher ME, Chalabrozy A, Blake SM, Mitre R, Popov N, Eilers M, et al. USP28 counteracts Fbw7 in intestinal homeostasis and cancer. Cancer Res. 2015;75:1181–6.

123. Reiterer V, Figueras-Puig C, Le Guerroue F, Confalonieri S, Vecchi M, Jalapothu D, et al. The pseudophosphatase STYX targets the F-box of Fbw7 modulates substrate degradation and activity. FEBS Lett. 2020;594:7067–73.

124. Zhang Q, Li X, Cui K, Liu C, Wu M, Prochownik EV, et al. The MAPK3–TRIM25–FBXW7 axis affects c-Myc protein stability and tumor development. Cell Death Differ. 2020;27:420–33.

125. Dangles-Marie M, Cacheux W, Rouleau E, Lazartigues J, Girard E, Briaux A, Mariani P, Richon S, Vacher S, Buecher B, Richard-Molard M, Jeannot E, Servant N, Parkinson D, Mariotte S, Irie Y, Irie A. Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. Oncotarget. 2017;8(1):464–76.

126. Zhang Q, Li X, Cui K, Liu C, Wu M, Prochownik EV, et al. The MAPK3–TRIM25–FBXW7 axis affects c-Myc protein stability and tumor development. Cell Death Differ. 2020;27:420–33.
Galindo-Moreno M, Giráldez S, Limón-Mortés MC, Belmonte-Fernández A, Sáez C, Japón MA, et al. p53 and FBXW7: Sometimes Two Guardians Are Worse than One. Cancers (Basel). 2020;12(4):985–9.

Tripathi V, Kaur E, Khurat SS, Hussain M, Damodaran AP, Kulshrestha S, et al. Abrogation of FBW7alpha-dependent p53 degradation enhances p53’s function as a tumor suppressor. J Biol Chem. 2019;294:13224–32.

Craig DW, O’Shaughnessy JA, Kiefer JA, Aldrich J, Sinan S, Moses TM, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013;12:104–16.

Yokobori T, Mimori K, Iwatsuki I, Iishi H, Onoyama I, Fukagawa T, et al. p53-Related FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 2009;69:3788–94.

Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer YE, et al. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Res. 2017;77:3527–39.

Huangfu D, Liu A, Rakeman AS, Murcia NS, Niswander L, Anderson KV. p53 and FBXW7: Sometimes Two Guardians Are Worse than One. Cancers (Basel). 2020;12(4):985–9.

Kourtis N, Moubarak RS, Aranda-Orgilles B, Lui K, Aydin IT, Trimarchi J, et al. FBXO45-MYCBP2 interaction of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci U S A. 2016;113:5357–32.

Kourtsi N, Moubarak RS, Aranda-Orgilles B, Lui K, Aydin IT, Trimarchi J, et al. FBXW7 modulates cellular stress response and metastatic potential through HSFI post-translational modification. Nat Cell Biol. 2015;17:322–32.

Kuchay S, Giorgi C, Simoncini D, Pagan J, Missiroli S, Saraf A, et al. PTEN counteracts FBXL2 to promote IP3R3- and Ca(2+)-mediated apoptosis limiting tumour growth. Nature. 2017;546:554–8.

Richter KT, Kschonsak YT, Vodicnik S, Hoffmann I. FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation. Cell Death Differ. 2020;27:758–72.

Saffie R, Zhou N, Roland D, Onder O, Basur V, Campbell S, et al. FBXW7 triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells. Cancer Res. 2020;80:2988–311.

Shiba-Ishii A, Hong J, Hirokawa T, Kim Y, Nakagawa T, Sakashita S, et al. Stratifin Inhibits SCF (FBW7) Formation and Blocks Ubiquitination of Oncoproteins during the Course of Lung Adenocarcinogenesis. Clin Cancer Res. 2019;25:2809–20.

Staropoli JF, McDermott C, Martinat C, Schulman B, Abelson H, Lee K, et al. Dynamic evaluation of somatic POLE exonuclease domain mutations. Nat Cell Biol. 2020;22:224–35.

Wang Y, Zhang P, Wang Y, Zhan P, Liu C, Mao J-H, Wei G. Distinct Interactions of FBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer. Cancer Res. 2017;77:1983–96.

Baek K, Krist DT, Prabu JR, Hill S, Kugel M, Neumera LM, et al. NEDD8 nucleates a multi-valent cullin-RING-UBE2D ubiquitin ligation assembly. Nature. 2020;578:461–6.

Hill S, Reichermer K, Scott DC, Samentar L, Coulombe-Huntington J, IZZI L, et al. Robust cullin-RING-LUBA ubiquitin ligation network revealed by systematic quantitative proteomics. Cell. 2021;184:3022–3040 e3028.

Welcker M, Clurman BE, Ras activites regulates cyclin E degradation by the FBW7 pathway. Proc Natl Acad Sci U S A. 2005;102:9649–54.

Thompson BJ, Buonamici S, Sulis ML, Palermo T, Villans T, Basso G, et al. SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukaemia. J Exp Med. 2007;204:1825–35.

Pan L, Pan X, Wang Y, Zhang P, Liu C, Mao J-H, Wei G. Distinct Interactions of FBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer. Cancer Res. 2017;77:1983–96.

Pashkova N, Gakhar L, Winistorfer SC, Yu L, Ramaswamy S, Piper RC. Multisite Phosphorylation by Cdk2 and GSK3 Controls Cyclin E Degradation. Mol Cell. 2003;12:381–92.

Welcker M, Singer J, Loeb KR, Grin J, Bleicher A, Gurien-West M, et al. Multisite Phosphorylation by Cdks2 and GSK3 Controls Cyclin E Degradation. Mol Cell. 2003;12:381–92.
193. Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, Priyadarshini R, Hussain M, Attri P, Kaur E, Tripathi V, Priya S, et al. BLM
197. Yu X, Gao F, Li W, Zhou L, Liu W, Li M. Formononetin inhibits tumor growth by suppression of EGFR-AKT-MCL-1 axis in non-small cell lung cancer. J Exp Clin Cancer Res. 2020;39:62–78.
198. Liu L, Zhao X, Zhao L, Li J, Yang H, Zhu Z, et al. Arginine Methylation of SREBP1a via PRMT5 Promotes De Novo Lipogenesis and Tumor Growth. Cell Metab. 2005;1:379–91.
200. He D, Ma Z, Fang C, Ding J, Yang W, Chen P, et al. Pseudophosphatase JW, et al. Control of lipid metabolism by phosphorylation-dependent targets KLF5 for ubiquitin-mediated degradation and suppress breast cell proliferation. Cancer Res. 2010;70:4728–38.
201. St-Denis N, Gupta GD, Lin ZY, Gonzalez-Badillo B, Veri AO, Knight JDR, Zhao D, Zheng HQ, Zhou Z, Chen C. The Fbw7 tumor suppressor gene. Nat Rev Cancer. 2002;2:442–54.
202. Huo T, Yang W, Chao L, Xin Z, Zhongtang L, Cheng G, Yingmin Y, Qingguang L. Fbw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 2014;13:110–22.
203. Huang KK, Ramnarayan K, Zhu F, Sivastava S, Xu C, Tan ALK, et al. Genomic and epigenomic profiling of high-risk intestinal metastasis reveals molecular determinants of progression to gastric cancer. Cancer Cell. 2018;33:137–150 e135.
204. Zhang Q, Zhang Y, Parsels JD, Lohse I, Lawrence TS, Pasca di Magliano M, et al. Fbw7 Deletion Accelerates Kras(G12D)-Driven Pancreatic Tumorigenesis via Yap Accumulation. Neoplasia. 2016;18:666–73.
205. Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, Krishnan S, Velasco ZFP36/TTP protects against ferroptosis by regulating autophagy signalization and resistance to cancer therapy. Trends. Cancer. 2019;5:283–96.
206. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason A, et al. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO J. 2016;35:2192–212.
207. Barrette AM, Ronik H, Joshi T, Mussa Z, Mehotra M, Bourc A, et al. Anti-inflammatory signalling by downregulating C/EBPdelta and its target genes in preclinical glioblastoma models. Neuro Oncol. 2021;23:241.
208. Balamurugan A, Savov V, Brunnier A, Bolin S, Weisshaupl H, Malysyka A, et al. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO J. 2016;35:2192–212.
209. Zhang Q, Mady ASA, Ma Y, Ryan C, Lawrence TS, Nikolovska-Coleska Z, et al. The WD40 domain of FBW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response. Nucleic Acids Res. 2019;47:4039–53.
210. Zhang Q, Karnack D, Tan M, Lawrence TS, Morgan MA, Sun Y. FBXW7 facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4. Mol Cell. 2015;61:419–33.
211. Wang J, Chan B, Tong M, Paung Y, Jo U, Martin D, et al. Prolyl isomerization of FAPα20 catalyzed by PIN1 regulates the Fanconi anemia pathway. PLoS Genet. 2019;15:e1007983.
212. Wang J, Chan B, Tong M, Paung Y, Jo U, Martin D, et al. Prolyl isomerization of PDK3 targets KLF5 for ubiquitin-mediated degradation and suppress breast cell proliferation. Cancer Res. 2010;70:4728–38.
213. Zhao J, Wang Y, Mu C, Xu Y, Sang J. MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NIDCD1 in breast and ovarian cancer cells. Oncogene. 2017;36:5023–34.
214. Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, Priyadarshini R, Hussain M, Attri P, Kaur E, Tripathi V, Priya S, et al. BLM
197. Yu X, Gao F, Li W, Zhou L, Liu W, Li M. Formononetin inhibits tumor growth by suppression of EGFR-AKT-MCL-1 axis in non-small cell lung cancer. J Exp Clin Cancer Res. 2020;39:62–78.
198. Liu L, Zhao X, Zhao L, Li J, Yang H, Zhu Z, et al. Arginine Methylation of SREBP1a via PRMT5 Promotes De Novo Lipogenesis and Tumor Growth. Cell Metab. 2005;1:379–91.
200. He D, Ma Z, Fang C, Ding J, Yang W, Chen P, et al. Pseudophosphatase STYX promotes tumor growth and metastasis by inhibiting FBXW7 function in colorectal cancer. Cancer Lett. 2019;49:53–65.
201. St-Denis N, Gupta GD, Lin ZY, Gonzalez-Badillo B, Veri AO, Knight JDR, Zhao D, Zheng HQ, Zhou Z, Chen C. The Fbw7 tumor suppressor gene. Nat Rev Cancer. 2002;2:442–54.
202. Huo T, Yang W, Chao L, Xin Z, Zhongtang L, Cheng G, Yingmin Y, Qingguang L. Fbw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 2014;13:110–22.
203. Huang KK, Ramnarayan K, Zhu F, Sivastava S, Xu C, Tan ALK, et al. Genomic and epigenomic profiling of high-risk intestinal metastasis reveals molecular determinants of progression to gastric cancer. Cancer Cell. 2018;33:137–150 e135.
236. Diaz VM, de Herreros AG. F-box proteins: Keeping the epithelial-to-mesenchymal transition (EMT) in check. Semin Cancer Biol. 2016;36:71–9.
238. Hong X, Liu W, Song R, Shah JJ, Feng X, Tsang CK, et al. SOX9 is targeted for proteasomal degradation by the E3 ligase FBW7 in response to DNA damage. Nucleic Acids Res. 2016;44:8855–69.
241. Yumimoto K, Akiyoshi S, Ueo H, Sagara Y, Onoyama I, Ueo H, et al. F-box protein FBW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. Oncotarget. 2015;6:8016310–25.
250. Kakihana M, Ohira T, Chan D, Webster RB, Kato H, Drabkin HA, et al. Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-gamma signalling. Nat Cell Biol. 2020;22:591–602.
256. Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P. Maximizing the Therapeutic Potential of HSP90 Inhibitors. Mol Cancer Res. 2015;13:1445–51.
257. Lu X, Xiao L, Wang L, Ruden DM. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem Pharmacol. 2012;83:995–1004.
258. Song X, Shen L, Tong J, Kuang C, Zeng S, Schoen RE, et al. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer. Theranostics. 2020;10:8089–110.
259. Tong J, Tan S, Nikolaevska-Coleska Z, Yu J, Zou F, Zhang L. FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors. Mol Cancer Ther. 2017;16:1979–88.
260. He L, Torres-Lockhart K, Forster N, Ramakrishnan S, Greninger P, Garnett MJ, et al. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov. 2013;3:324–37.
261. Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. Mol Cancer. 2021;20:15–41.
262. Beltran H, Rickman DS, Park K, Chae SS, Sponer A, Macdonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–95.
263. Wang B, Qu C, Zhao Q, Wang H, Wei J, Meng L, et al. Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review. Ann Palliat Med. 2021;10:8340–5.
264. Villaruz LC, Socinski MA. Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. Lung Cancer. 2014;83:300–1.
265. Mao J-H, Kim I-J, Wu D, Climent J, Kang HC, DelRosario R, Balmain A. FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression. Science. 2008;321:1499–502.
266. Bill R, Montani M, Blum B, Dufour JF, Escher R, Buhlmann M. Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. Hepatology. 2018;67:834–46.
267. Xiao Y, Yin C, Wang Y, Lv H, Wang W, Huang Y, et al. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy. Mol Oncol. 2018;12:883–95.
268. Ock CY, Son B, Keam B, Lee SY, Moon J, Kwik H, et al. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2016;142:873–83.
269. Rodon J, Juric D, Tabernero J, Janku F, Burris HA, JHMA, et al. Mcl-1 and FBW7 control a dominant survival pathway underly- ing HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. J Cancer Res Clin Oncol. 2016;142:873–83.
270. Yang Z, Hu N, Wang W, Hu W, Zhou S, Shi J, et al. Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation. Cancer Res. 2022;82:497–509.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.